<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-06-24">24 June 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Andrew</forename><forename type="middle">J</forename><surname>Ullmann</surname></persName>
							<email>andrew.ullmann@uni-wuerzburg.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Internal Medicine II</orgName>
								<orgName type="department" key="dep2">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep3">Division of Infectious Diseases</orgName>
								<orgName type="institution">Universitätsklinikum, Julius Maximilian&apos;s University</orgName>
								<address>
									<addrLine>Oberdürrbacher Str. 6</addrLine>
									<postCode>97080</postCode>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Schmidt-Hieber</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Clinic for Hematology, Oncology und Tumor Immunology</orgName>
								<orgName type="institution">Helios Clinic Berlin-Buch</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><surname>Hartmut Bertz</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Hematology/Oncology</orgName>
								<orgName type="institution">University of Freiburg Medical Center</orgName>
								<address>
									<postCode>79106</postCode>
									<settlement>Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Werner</forename><forename type="middle">J</forename><surname>Heinz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Internal Medicine II</orgName>
								<orgName type="department" key="dep2">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep3">Division of Infectious Diseases</orgName>
								<orgName type="institution">Universitätsklinikum, Julius Maximilian&apos;s University</orgName>
								<address>
									<addrLine>Oberdürrbacher Str. 6</addrLine>
									<postCode>97080</postCode>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Kiehl</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Klinikum Frankfurt (Oder)</orgName>
								<orgName type="institution">Medical Clinic I</orgName>
								<address>
									<settlement>Frankfurt (Oder)</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">William</forename><surname>Krüger</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Haematology and Oncology</orgName>
								<orgName type="department" key="dep2">Palliative Care</orgName>
								<orgName type="institution" key="instit1">Stem Cell Transplantation</orgName>
								<orgName type="institution" key="instit2">University Hospital Greifswald</orgName>
								<address>
									<settlement>Greifswald</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sabine</forename><surname>Mousset</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Palliativmedizin und interdisziplinäre Onkologie</orgName>
								<orgName type="institution" key="instit1">Medizinische Klinik III</orgName>
								<orgName type="institution" key="instit2">St. Josefs-Hospital Wiesbaden</orgName>
								<address>
									<settlement>Wiesbaden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Neuburger</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Sindelfingen-Böblingen Clinical Centre</orgName>
								<orgName type="department" key="dep2">Medical Department I</orgName>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Division of Hematology and Oncology</orgName>
								<orgName type="institution">Klinikverbund Südwest</orgName>
								<address>
									<settlement>Sindelfingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Silke</forename><surname>Neumann</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Medical Oncology</orgName>
								<orgName type="institution">AMO MVZ</orgName>
								<address>
									<settlement>Wolfsburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olaf</forename><surname>Penack</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Hematology, Oncology and Tumorimmunology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerda</forename><surname>Silling</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Internal Medicine IV</orgName>
								<orgName type="institution">University Hospital RWTH Aachen</orgName>
								<address>
									<settlement>Aachen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">&amp;</forename><surname>Jörg</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Janne</forename><surname>Vehreschild</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department I of Internal Medicine</orgName>
								<orgName type="institution">German Centre for Infection Research</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hermann</forename><surname>Einsele</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Internal Medicine II</orgName>
								<orgName type="department" key="dep2">Division of Hematology and Oncology</orgName>
								<orgName type="department" key="dep3">Division of Infectious Diseases</orgName>
								<orgName type="institution">Universitätsklinikum, Julius Maximilian&apos;s University</orgName>
								<address>
									<addrLine>Oberdürrbacher Str. 6</addrLine>
									<postCode>97080</postCode>
									<settlement>Würzburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Georg</forename><surname>Maschmeyer</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Hematology, Oncology and Palliative Care</orgName>
								<orgName type="institution">Klinikum Ernst von Bergmann</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="department">Bonn-Cologne</orgName>
								<orgName type="institution">University Hospital of Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-06-24">24 June 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">DC14E641716C25C10EFD0F0A21157BE0</idno>
					<idno type="DOI">10.1007/s00277-016-2711-1</idno>
					<note type="submission">Received: 28 January 2016 / Accepted: 28 May 2016 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:36+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Infections</term>
					<term>Viral</term>
					<term>Fungal</term>
					<term>Bacteria</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge.</s><s>This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology).</s><s>A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group.</s><s>The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases.</s><s>The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations.</s><s>This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Infectious complications remain a clinical challenge in the setting of allogeneic haematopoietic stem cell transplantation (allo-HCT).</s><s>Particular during the early phase after allo-HCT, mortality rates for infections are high <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>After the first publication of recommendations from our group in 2003, <ref type="bibr" target="#b2">[3]</ref> numerous new results of trials have been published and implemented into daily patient care.</s><s>With this updated guideline, AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology) pursues a step forward to include the entire patient history up right from the beginning of the preparation of patients through the entire post allo-HCT time period.</s></p><p><s>This guideline focuses on the adult patient population only and is partitioned into four parts: (a) general precautions and prevention measures, (b) pre-transplantation (screening) phase, (c) prophylactic treatment, and (d) immunization strategies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>Several steps were undertaken to develop the updated guideline: The first step was defining a group of specialists.</s><s>They were enlisted by the AGIHO of the DGHO with a designated coordinator.</s><s>The coordinator was responsible to manage the efforts of the group.</s><s>The group of authors consisted of 14 certified internists, including 13 certified haematologists, and 5 certified infectious diseases specialists.</s><s>Four authors are triple certified in internal medicine, infectious diseases, and haematology/oncology.</s></p><p><s>Predefined topics were elaborated by subgroups and then presented to the entire group for discussions.</s><s>This included several face-to-face meetings, which were complemented by conference calls.</s><s>Once the group had consensus with their results, the preliminary recommendations of the group were presented to the entire AGIHO assembly for review, discussions, modification, and final approval.</s><s>All recommendations were made on the basis of available data providing evidence-based medicine.</s><s>The guideline utilized the latest version of the strength of recommendation and quality of evidence published by the ESCMID (Table <ref type="table" target="#tab_0">1</ref>) <ref type="bibr">[4]</ref>.</s><s>Specific topics related to cord blood or haplo-identical transplant recipients are not addressed by this guideline.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General precautions</head><p><s>An allo-HCT requires certain assessment procedures, which are basically standardized (e.g.</s><s>JACIE by the EBMT).</s><s>Herein, we touch off on a few basic standardized requirements.</s></p><p><s>Patients' rooms should be equipped with air-filtered systems to keep spore counts low and, thus, preventing nosocomial fungal diseases (BII) <ref type="bibr">[5]</ref><ref type="bibr">[6]</ref><ref type="bibr">[7]</ref><ref type="bibr">[8]</ref><ref type="bibr">[9]</ref>.</s><s>Further, nearby construction activities should be kept to a minimum (AII).[10]</s><s>Isolation of the stem cell recipients in a single hospital room under conditions of laminar airflow or positive pressure HEPA filtration (&gt;12 exchanges per hour) is generally recommended.</s></p><p><s>However, randomized controlled trials focusing on HEPA filter efficacy against viral infections are lacking.</s><s>Especially respiratory virus outbreaks, including seasonal pathogens such as respiratory syncytial virus (RSV) and influenza, are not prevented by HEPA filtrations <ref type="bibr">[11]</ref>.</s><s>Genotyping of RSV outbreaks demonstrated that more than two thirds were hospital acquired <ref type="bibr">[12]</ref><ref type="bibr">[13]</ref><ref type="bibr">[14]</ref><ref type="bibr">[15]</ref>.</s><s>These results underscored the important necessity of infection control measures (i.e.</s><s>barrier precautions) to prevent exposure directly at the patients' site (AII).</s></p><p><s>Some debate usually arises on the topic of appropriate dietary needs for patients after allo-HCT.</s><s>The rule of thumb Bcook it, peal it, or forget it^is easy to understand.</s><s>However, there is a lack of appropriate literature on this specific topic.</s><s>On the other hand, the evidence is clearer for the prevention of specific infections, e.g.</s><s>listeria or other agents a : published abstract (presented at an international symposium or meeting)</s></p><p><s>causing infectious diarrhea (BII) <ref type="bibr">[16,</ref><ref type="bibr">17]</ref>.</s><s>Contact precautions and hand disinfection (incl.</s><s>repeated teaching on this matter) can prevent nosocomial infection (AII) <ref type="bibr">[18]</ref>.</s><s>Healthcare workers (HCW) with transmissible diseases (e.g.</s><s>herpes, infectious gastroenteritis, respiratory tract infections) should be restrained from direct patient care to prevent any nosocomial spread of their disease (AIII) <ref type="bibr">[19]</ref>.</s><s>Some hospital facilities have recovered microbes (e.g.</s><s>Legionella spp.) from their drinking water.</s><s>In order to prevent transmission in high-risk patients, water filters provide a protective solution though regular testing remains a necessity (AII) <ref type="bibr">[20]</ref><ref type="bibr">[21]</ref><ref type="bibr">[22]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pre-transplantation (screening) phase</head><p><s>A comprehensive pre-transplant assessment of the allo-HCT recipient for infectious complications is a valuable tool to identify patients at increased risk for distinct infectious diseases.</s><s>Syphilis, tuberculosis, Toxoplasma gondii, HIV, hepatitis B and C viruses, and Herpes viridae usually persist lifelong in the host after primary infection and can be reactivated under certain conditions.</s><s>As a consequence, all candidates for allo-HCT should undergo a test for IgG antibodies specific for viral diseases, syphilis, and toxoplasmosis.</s><s>False negative results particularly could occur in the context of CLL, multiple myeloma, previous antibody treatment (e.g.</s><s>rituximab), or might be false positive after IVIG application or blood product transfusion.</s><s>In any case, all patients tested IgG-seronegative strictly remain on preventive measures to avoid de novo infection prior to allo-HCT and afterwards.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Specific viruses</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Herpes viridae</head><p><s>All candidates for allo-HCT should be tested for CMV, EBV, and VZV IgG antibodies to determine their risk for reactivation or de novo infection (AIII) <ref type="bibr">[23]</ref><ref type="bibr">[24]</ref><ref type="bibr">[25]</ref>.</s><s>Due to the high prevalence of HSV in the patient population, further antibody testing for HSV is not mandatory (CII t ) <ref type="bibr">[26]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hepatitis B</head><p><s>Prior to allo-HCT, besides hepatitis B virus (HBV) antibody panels, additional testing for hepatitis B surface antigen (HBsAg) should be performed <ref type="bibr">[27,</ref><ref type="bibr">28]</ref>.</s><s>If tested positive for HBsAg or for anti-HBc, further HBV-DNA assessment for active replication is crucial (AII).</s><s>If considered to be diagnosed with active hepatitis (e.g.</s><s>viral replication), initiation of antiviral treatment prior to allo-HCT should be considered</s></p><formula xml:id="formula_0">(AIII) [29].</formula><p><s>There is a reported risk of up to 50 % for reverse seroconversion after allo-HCT if a patient is anti-HBc positive but has no detectable viral replication (resolved HBV infection) <ref type="bibr">[30]</ref><ref type="bibr">[31]</ref><ref type="bibr">[32]</ref>.</s><s>HBV-vaccination after allo-HCT might alleviate this risk <ref type="bibr">[33]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hepatitis C</head><p><s>Serologic testing for hepatitis C virus (HCV) is recommended.</s><s>Serologically positive patients should receive quantitative testing for HCV-RNA viral load (AIII).</s><s>Patients with chronic hepatitis C should receive a further diagnostic assessment, e.g., fibroscan or a liver biopsy to rule out liver fibrosis or cirrhosis.</s><s>In case of liver cirrhosis or fibrosis, the conditioning regimen should try to avoid TBI, oral busulfan, or cyclophosphamide to minimize risk of hepatic sinusoidal occlusion syndrome (SOS) (BIII) <ref type="bibr">[34]</ref><ref type="bibr">[35]</ref><ref type="bibr">[36]</ref><ref type="bibr">[37]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hepatitis E</head><p><s>Hepatitis E virus (HEV) is detected in immunocompromised patients.</s><s>Limited information is available on the real incidence of HEV infection in recipients of allo-HCT <ref type="bibr">[38,</ref><ref type="bibr">39]</ref>.</s><s>Mostly self-limited reactivation cases are published though chronic forms have been described as well.</s><s>Serologic testing for HEV prior to allo-HCT is recommended (BIII).</s><s>HEV should be considered as a differential diagnosis in patients after allo-HCT with elevated liver function tests <ref type="bibr">[39]</ref><ref type="bibr">[40]</ref><ref type="bibr">[41]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HIV</head><p><s>HIV testing prior to allo-HCT is recommended.</s><s>HIV-infected patients should be carefully evaluated for allo-HCT.</s><s>Though HIV seropositivity per se is not a contraindication for allo-HCT <ref type="bibr" target="#b3">[42]</ref>.</s><s>If allo-HCT seems feasible, a donor screening for CCR5-Delta 32 deletion could be considered in patients with CCR5 tropism to potentially control HIV infection post-allo-HCT (BIII) <ref type="bibr" target="#b4">[43,</ref><ref type="bibr" target="#b5">44]</ref>.</s><s>Toxicity permitting, antiretroviral therapy should be continued throughout of the post-transplantation phase (AII) <ref type="bibr" target="#b6">[45]</ref>.</s><s>However, recurring interruptions with low drug levels may induce viral resistance, and an interrupted treatment should not be reinstated until the patient has sufficiently recovered to allow stable tablet intake (BIII).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Syphilis</head><p><s>Serologic testing for syphilis is recommended.</s><s>Frequently TPHA/TPPA or VDRL are utilized.</s><s>Important are the combinations of nontreponemal (e.g.</s><s>VDRL) and treponemal tests.</s><s>If a nontreponemal test is positive, confirmation of infection with treponemal test (e.g.</s><s>TPPA or TP-EIA) should be performed.</s><s>In case of an active infection or unclear whether the patient received an adequate treatment in the past, a treatment with penicillin should be instituted (BIII) <ref type="bibr" target="#b7">[46]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxoplasmosis</head><p><s>All candidates for allo-HCT should undergo serologic testing for toxoplasmosis.</s><s>If the serology testing for toxoplasmosis IgG is positive, patients have a risk of toxoplasmosis reactivation, especially if the donor is serologically negative for toxoplasmosis <ref type="bibr" target="#b8">[47]</ref>.</s><s>Some centres propagate regular PCR testing <ref type="bibr" target="#b9">[48]</ref>.</s><s>Since the incidence in Europe is very low, regular toxoplasmosis DNA through PCR screening is not recommended (DIII).</s><s>This is of course different in patients with clinical symptoms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tuberculosis</head><p><s>Thorough evaluation of the medical history can identify patients at risk for latent or active tuberculosis infection (AIII).</s><s>As most candidates have received chemotherapy or immunosuppressive treatment prior to evaluation for allo-HCT, a tuberculin skin test might be false negative and therefore cannot be recommended in this setting (DIII).</s><s>If the medical history is suggestive of prior tuberculosis exposure, an interferongamma-release assay (IGRA) can be considered (BIII) <ref type="bibr" target="#b10">[49]</ref>.</s><s>However, a reduced sensitivity in immunocompromised patients has been demonstrated as well <ref type="bibr" target="#b11">[50,</ref><ref type="bibr" target="#b12">51]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prophylaxis and prevention</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prevention of bacterial infections (screening for bacterial colonization)</head><p><s>In this era of easy accessibility of antibiotics, clinicians are facing the growing challenge of multi-resistant bacteria (e.g.</s><s>vancomycin-resistant Enterococci (VRE), methicillinresistant Staphylococcus aureus (MRSA), extendedspectrum beta-lactamase producing bacteria (ESBL), metallo-ß-lactamase-producing bacteria (MBL)).</s><s>Colonization with certain multi-resistant bacteria is predictive for developing bloodstream infection, and knowledge of colonization status may therefore guide empirical antibiotic treatment, although this strategy has not been demonstrated to improve outcomes <ref type="bibr" target="#b13">[52,</ref><ref type="bibr" target="#b14">53]</ref>.</s><s>We recommend screening procedures for multi-resistant bacteria, especially in institutions with a known high prevalence (BII) <ref type="bibr" target="#b15">[54,</ref><ref type="bibr" target="#b16">55]</ref>.</s><s>Since the sensitivity of the screening methods is low, repeated testing (e.g.</s><s>weekly rectal swabs) would be required <ref type="bibr" target="#b17">[56]</ref><ref type="bibr" target="#b18">[57]</ref><ref type="bibr" target="#b19">[58]</ref>.</s><s>Contact precautions between medical staff and patients remain to be necessary and separate sanitary facilities need to be guaranteed to exclude cross-patient transfer of multiresistant bacteria <ref type="bibr" target="#b20">[59,</ref><ref type="bibr" target="#b21">60]</ref>.</s></p><p><s>Antibiotic prophylaxis (e.g.</s><s>ciprofloxacin) demonstrated its efficacy by reducing the incidence of Gram-negative sepsis during neutropenia without any significant change in mortality <ref type="bibr" target="#b22">[61,</ref><ref type="bibr" target="#b23">62]</ref>.</s><s>All-cause mortality was reduced only in metaanalysis <ref type="bibr" target="#b24">[63]</ref>.</s><s>At institutions with a low rate of multi-resistant gram-negative bacteria, antibacterial prophylaxis remains a reasonable choice to reduce the incidence of Gram-negative sepsis during neutropenia (AII r ) <ref type="bibr" target="#b23">[62,</ref><ref type="bibr" target="#b25">[64]</ref><ref type="bibr" target="#b26">[65]</ref><ref type="bibr" target="#b27">[66]</ref><ref type="bibr" target="#b28">[67]</ref>. Encapsulated bacteria such as Streptococcus pneumoniae or Haemophilus influenzae often cause severe bacterial infections in the late phase after transplantation <ref type="bibr" target="#b29">[68]</ref><ref type="bibr" target="#b30">[69]</ref><ref type="bibr" target="#b31">[70]</ref>.</s><s>In patients with chronic GVHD (graft-versus-host disease) on immunosuppressive therapy, antibiotic prophylaxis against these bacteria for disease prevention might be useful until immunizations can be applied (BIII).</s><s>Antibiotic selection should be guided by local antibiotic resistance patterns.</s><s>In patients without chronic GVHD, systemic antibiotic prophylaxis is not recommended after reconstitution of the neutrophils (DIII).</s></p><p><s>The value of selective gut decontamination is frequently debated and the literature points out that sepsis rates are increased and mortality outcomes were significantly worse in patients with lower intestinal diversity; therefore, no recommendation was made <ref type="bibr" target="#b32">[71]</ref><ref type="bibr" target="#b33">[72]</ref><ref type="bibr" target="#b34">[73]</ref><ref type="bibr" target="#b35">[74]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prophylaxis against Pneumocystis pneumonia</head><p><s>Pneumocystis jirovecii (previously named Pneumocystis carinii) pneumonia has been noted in allo-HCT recipients with an incidence of approximately 5-16 % without adequate prophylaxis and occurred at a median of 9 weeks after allo-HCT.</s><s>Despite intensive treatment, mortality rates are as high as 89 % during the first 6 months and approximately 40 % after the first 6 months following allo-HCT <ref type="bibr" target="#b36">[75,</ref><ref type="bibr" target="#b37">76]</ref>.</s></p><p><s>Prophylaxis against Pneumocystis jirovecii pneumonia is recommended for at least first 6 months after allo-HCT to prevent Pneumocystis jirovecii pneumonia-associated death (AII t ).</s><s>However, patients might require prophylaxis for prolonged periods of time.</s><s>Recommended prophylactic regimens are similar to regimens in HIV/AIDS patients.</s><s>Therefore, patients on immunosuppressive medications or active GVHD should remain on prophylaxis <ref type="bibr" target="#b38">[77]</ref>.</s><s>Once immunosuppressive medications are discontinued or no active GVHD is noted, prophylaxis may be discontinued assuming a CD4 + /CD3 + lymphocyte count of 200/μL or higher (BII t ).</s><s>Thus monitoring of CD4 + /CD3 + lymphocytes could be continued until the threshold is confirmed by repeated testing (BII t ) <ref type="bibr" target="#b39">[78]</ref>.</s><s>The CD4 + /CD3 + lymphocyte count of 200/μL as a discontinuation criterion is not confirmed in the allogeneic setting, and therefore, an individual decision to discontinue can be considered (CIII).</s></p><p><s>The prophylactic treatment of choice is the fixed combination of trimethoprim (80 mg) and sulfamethoxazole (400 mg) once daily thrice weekly (AII t ) <ref type="bibr" target="#b40">[79]</ref><ref type="bibr" target="#b41">[80]</ref><ref type="bibr" target="#b42">[81]</ref><ref type="bibr" target="#b43">[82]</ref>.</s><s>In case of intolerance to the trimethoprim/sulfamethoxazole therapy, aerosolized pentamidine (300 mg) every 4 weeks (BII t ) or atovaquone (750 or 1500 mg daily) (BII t ) is recommended <ref type="bibr" target="#b44">[83]</ref><ref type="bibr" target="#b45">[84]</ref><ref type="bibr" target="#b46">[85]</ref><ref type="bibr" target="#b47">[86]</ref><ref type="bibr" target="#b48">[87]</ref><ref type="bibr" target="#b49">[88]</ref><ref type="bibr" target="#b50">[89]</ref>.</s><s>Dapsone (100 mg) cannot be recommended (DII t ) <ref type="bibr" target="#b51">[90]</ref>.</s><s>Protective efficacy against Pneumocystis appears to be less with these alternative drugs compared to trimethoprim/ sulfamethoxazole <ref type="bibr" target="#b45">[84,</ref><ref type="bibr" target="#b47">86,</ref><ref type="bibr" target="#b51">[90]</ref><ref type="bibr" target="#b52">[91]</ref><ref type="bibr" target="#b53">[92]</ref><ref type="bibr" target="#b54">[93]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antifungal prophylaxis in allo-HCT</head><p><s>Invasive fungal diseases (IFDs) are severe complications associated with prolonged hospital length of stay, costs, longterm treatment, and high mortality <ref type="bibr" target="#b55">[94]</ref>.</s><s>Approximately two thirds of the IFD develop in allo-HCT patients after leukocyte recovery <ref type="bibr" target="#b56">[95,</ref><ref type="bibr" target="#b57">96]</ref>.</s><s>Furthermore, intensifying immunosuppression for treatment of transplant rejection or GvHD and CMV infection impose an imminent risk for IFD <ref type="bibr" target="#b58">[97,</ref><ref type="bibr" target="#b59">98]</ref>.</s></p><p><s>The incidence of invasive aspergillosis (IA) varies between reports and may reach 23 % <ref type="bibr" target="#b55">[94,</ref><ref type="bibr" target="#b60">99]</ref>.</s><s>Primary prophylaxis is highly recommended since diagnostic tools do not present with sufficient sensitivity numbers.</s><s>This is mirrored in studies with a significant number of post-mortem diagnoses of fungal diseases <ref type="bibr" target="#b61">[100]</ref><ref type="bibr" target="#b62">[101]</ref><ref type="bibr" target="#b63">[102]</ref>.</s><s>In patients diagnosed with IA, mortality rates of up to 60 % have been reported despite adequate treatment <ref type="bibr" target="#b64">[103]</ref>.</s><s>Secondary prophylaxis is recommended prior to allo-HCT (BII) <ref type="bibr" target="#b65">[104]</ref>.</s></p><p><s>Invasive candidiasis, predominantly manifesting as candidemia, is the second most frequent IFD in allo-HCT patients.</s><s>Invasive candidiasis/candidemia typically manifests in patients with underlying conditions after being exposed to additional risk factors, e.g.</s><s>intravascular devices, broadspectrum antibiotic treatment, total parenteral nutrition, or Candida colonization <ref type="bibr" target="#b66">[105]</ref><ref type="bibr" target="#b67">[106]</ref><ref type="bibr" target="#b68">[107]</ref>.</s></p><p><s>The currently largest cohort of IFDs shows an 8 % share of mucormycosis in all IFDs in allo-HCT, followed by a number of other rare mould infections <ref type="bibr" target="#b55">[94]</ref>.</s><s>Approximately half of the patients diagnosed with mucormycosis are patients after allo-HCT <ref type="bibr" target="#b69">[108]</ref>.</s><s>The share of rare IFDs like those caused by the order of Mucorales or Fusarium spp.</s><s>appear to be increasing <ref type="bibr" target="#b55">[94,</ref><ref type="bibr" target="#b70">109]</ref>.</s><s>Newer agents like isavuconazole demonstrated favorable response rates in primary treatment against moulds; however, larger prophylaxis studies are still needed <ref type="bibr" target="#b71">[110]</ref><ref type="bibr" target="#b72">[111]</ref><ref type="bibr" target="#b73">[112]</ref>.</s></p><p><s>In Table <ref type="table" target="#tab_1">2</ref>, prophylactic recommendations are summarized.</s><s>Our group recently published recommendations for the treatment (i.e.</s><s>targeted therapy) of fungal diseases <ref type="bibr" target="#b74">[113]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Herpes simplex virus 1/2 prevention</head><p><s>Herpes viridae persist in the host after primary infection.</s><s>Up to 80 % of adults are HSV-seropositive and especially during immunosuppression HSV may begin to replicate.</s><s>Without prophylaxis allo-HCT recipients have a risk of approximately 80 % to reactivate during the early phase mainly during the first 4 weeks after allo-HCT <ref type="bibr">[19,</ref><ref type="bibr">137,</ref><ref type="bibr">138]</ref>.</s><s>Dissemination may lead to severe illness with substantial morbidity and mortality.</s><s>As a consequence, patients should receive acyclovir early on for the prevention of disease to reduce mortality (AI) [138-141] (Table <ref type="table" target="#tab_2">3</ref>).</s></p><p><s>The duration of prophylaxis should last for up to 30 days after allo-HCT (AI) <ref type="bibr">[139,</ref><ref type="bibr">141]</ref>.</s><s>However, exceptions are defined by recurrent episodes of HSV disease or risk of Varicella zoster disease.</s><s>In these situations, duration of acyclovir prophylaxis to prevent disease is prolonged to a year or longer especially during intensified immunosuppressive therapy (BII) <ref type="bibr">[142]</ref>.</s></p><p><s>Resistance to acyclovir is a rare event and mainly caused by reduced activity or mutations of viral thymidine kinase resulting in reduced activation of acyclovir in infected cells <ref type="bibr">[143,</ref><ref type="bibr">144]</ref>.</s><s>Breakthrough infections are noted but are usually described as clinically resistant since prophylaxis failure is explainable by decreased bioavailability of acyclovir.</s><s>In cases of real acyclovirresistant HSV, foscarnet susceptibility remains, and this agent is considered as an alternative treatment option for acyclovir-resistant disease (BII).</s><s>However, it cannot be recommended for routine prophylaxis due to its significant toxicity (DIII) <ref type="bibr">[145]</ref>.</s></p><p><s>It is presumed that valacyclovir and famciclovir are effective for the prevention of HSV reactivation; however, there are no clinical trials in allo-HCT to better support a recommendation (CIII) <ref type="bibr">[146,</ref><ref type="bibr">147]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Varicella zoster virus prevention</head><p><s>Since Varicella zoster virus (VZV) is highly contagious, patients with VZV disease should be isolated to prevent nosocomial spreading of viruses until all lesions are crusted (AIII) <ref type="bibr">[148,</ref><ref type="bibr">149]</ref>.</s><s>Patients should be informed of the easy transmission of VZV.</s><s>Allo-HCT recipients without adequate antiviral prophylaxis are at risk for disease, since up to two thirds develop herpes zoster, which mainly occurs 3 to 12 months after allo-HCT <ref type="bibr">[150]</ref>.</s><s>VZV seronegative family members, healthcare workers, other contact persons of allo-HCT recipients, or children without a history of Varicella or immunization, should be advised to receive a vaccination against VZV ideally at least 4 weeks prior to planned allo-HCT (BIII)</s></p><formula xml:id="formula_1">[151].</formula><p><s>Primary infection is rare and is associated with a high rate of mortality caused by frequent dissemination (e.g.</s><s>encephalitis, pneumonia, viscera, or hepatitis) <ref type="bibr">[150,</ref><ref type="bibr">152,</ref><ref type="bibr">153]</ref>.</s><s>Therefore, exposure of seronegative recipients to chickenpox, zoster or vaccinated persons who experience a rash after vaccination should be avoided to prevent primary disease or VZV-associated death (BIII).</s><s>If exposure to persons with chickenpox or zoster o c c u r s , p a s s i v e i m m u n i z a t i o n w i t h a n t i -V Z V hyperimmunoglobulin (Ig) within 96 h after exposure is considered optional (CIII), as efficacy has not been proven <ref type="bibr">[154,</ref><ref type="bibr" target="#b78">155]</ref>.</s><s>Antiviral therapy with valacyclovir 1 g po tid or acyclovir 800 mg qid should be administered (BIII) immediately to prevent disease in seronegative recipients.</s></p><p><s>Main antiviral prophylaxis recommendations are summarized in Table <ref type="table" target="#tab_2">3</ref>. Various authors <ref type="bibr" target="#b79">[156]</ref><ref type="bibr" target="#b80">[157]</ref><ref type="bibr" target="#b81">[158]</ref><ref type="bibr" target="#b82">[159]</ref> noted that even prolonged administration for approximately 1 year or longer is considered safe and there was no higher incidence of disease after drug discontinuation.</s><s>Longer than 12-month periods appears to be beneficial as long as patients remain on intensified immunosuppressive therapy (BIII).</s></p><p><s>If resistance to acyclovir is suspected, foscarnet or cidofovir are alternative agents (BIII) <ref type="bibr" target="#b83">[160]</ref>.</s><s>Brivudine is contraindicated in patients receiving 5-fluoropyrimidine derivatives and was not assessed in immunocompromised patients</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CMV disease prevention</head><p><s>All CMV-seronegative recipients ideally should receive a CMV-seronegative donor graft to prevent infection and reduce mortality (AII) <ref type="bibr">[25,</ref><ref type="bibr" target="#b84">161,</ref><ref type="bibr" target="#b85">162]</ref>.</s><s>To further prevent disease, CMV-seronegative recipients transplanted from a negative donor should only receive blood products from CMVseronegative donors upon availability.</s><s>Blood banks without a sufficient pool of CMV-negative donors should deliver only leukocyte-depleted red blood cells and thrombocytes (AII) <ref type="bibr" target="#b86">[163]</ref>.</s><s>However, data from various studies suggest if blood products are leukocytes reduced, testing for CMV-negative blood products is not needed for HSCT recipients (AII) <ref type="bibr" target="#b86">[163]</ref><ref type="bibr" target="#b87">[164]</ref><ref type="bibr" target="#b88">[165]</ref>.</s><s>Noteworthy, irradiation to prevent transfusionassociated GvHD does not inactivate CMV <ref type="bibr" target="#b87">[164,</ref><ref type="bibr" target="#b89">[166]</ref><ref type="bibr" target="#b90">[167]</ref><ref type="bibr" target="#b91">[168]</ref><ref type="bibr" target="#b92">[169]</ref><ref type="bibr" target="#b93">[170]</ref>.</s></p><p><s>Special risk factors for CMV infection or disease are T celldepleted graft, HLA-mismatched transplantation, steroid treatment, and acute or chronic GvHD <ref type="bibr" target="#b94">[171]</ref><ref type="bibr" target="#b95">[172]</ref><ref type="bibr" target="#b96">[173]</ref>.</s><s>All patients at risk for CMV disease should be screened regularly for pp65 antigenemia or by nucleic acid detection methods after allo-HCT (AII) <ref type="bibr" target="#b97">[174]</ref>.</s><s>The current standard to improve morbidity and lower mortality is the early initiation of a preemptive therapy against CMV (AII) <ref type="bibr" target="#b97">[174]</ref>.</s><s>Duration of screening is usually defined by the time period of the application of immunosuppressive agents or GVHD.</s></p><p><s>Anti-CMV prophylaxis can only be considered as an option.</s><s>The long-term administration of ganciclovir resulted in a delay of recovery from CMV-specific T cell immunity <ref type="bibr" target="#b98">[175]</ref>.</s></p><p><s>Valganciclovir is so far not officially approved in allo-HCT patients but has been applied in randomized trials <ref type="bibr" target="#b99">[176,</ref><ref type="bibr" target="#b100">177]</ref>.</s><s>In a randomized controlled trial, valganciclovir prophylaxis was not superior in reducing the incidence of CMV disease or death when compared with PCR-guided preemptive therapy.</s><s>Delay in virus-specific T cell reconstitution was not observed in patients receiving prophylaxis <ref type="bibr" target="#b100">[177]</ref>.</s><s>Administration of human immune  <ref type="bibr" target="#b177">[254]</ref> globulins for prophylaxis or therapy of CMV disease is generally not recommended (DII) <ref type="bibr" target="#b101">[178,</ref><ref type="bibr" target="#b102">179]</ref>.</s><s>Some investigators published efficacy of high-dose acyclovir or its prodrug valacyclovir in the prevention of CMV disease <ref type="bibr" target="#b103">[180]</ref><ref type="bibr" target="#b104">[181]</ref><ref type="bibr" target="#b105">[182]</ref><ref type="bibr" target="#b106">[183]</ref>.</s><s>However, acyclovir failed to prevent CMV disease in autologous transplantation and therefore, is not recommended for prophylaxis (DIII) <ref type="bibr" target="#b107">[184]</ref>.</s><s>Newer antiviral agents have been evaluated mainly in phase II trials.</s><s>Maribavir, an oral antiviral agent was studied for prophylaxis.</s><s>Maribavir inhibits the UL97 viral protein-kinase of human CMV.</s><s>Despite promising results in a phase II study, a phase III study could not confirm a benefit <ref type="bibr" target="#b108">[185]</ref><ref type="bibr" target="#b109">[186]</ref><ref type="bibr" target="#b110">[187]</ref>.</s><s>Another antiviral agent named CMX001 is an orally bioavailable lipid acyclic nucleoside phosphonate and is converted intracellularly to cidofovir diphosphate.</s><s>Brincidofovir (CMX001) is active in vitro against CMV, including ganciclovir-resistant strains and was assessed in a phase II trial with promising results in prophylaxis <ref type="bibr" target="#b111">[188]</ref>.</s><s>Letermovir (previously known as AIC246) is another anti-CMV agent with a novel mechanism of action targeting the viral terminase subunit pUL56, a component of the terminase complex.</s><s>This agent demonstrated dose-dependent prophylactic efficacy in a phase II trial <ref type="bibr" target="#b112">[189]</ref>.</s><s>If the ongoing phase III trials confirm these results, a paradigm shift may occur in the future.</s></p><p><s>New DNA-based vaccination strategies against CMV are being evaluated in clinical trials <ref type="bibr" target="#b113">[190]</ref>.</s></p><p><s>Main antiviral recommendations are noted in Table <ref type="table" target="#tab_2">3</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Epstein-Barr virus disease prevention</head><p><s>Factors associated with an enhanced risk for Epstein-Barr virus (EBV) replication and therefore infection after allo-HCT are a selective T cell depletion of the graft, a HLA-mismatched transplantation, the choice of an unrelated donor (especially haploidentical transplant recipients), and the use of T cell depleting antibodies, e.g.</s><s>alemtuzumab or ATG during conditioning <ref type="bibr" target="#b114">[191,</ref><ref type="bibr" target="#b115">192]</ref>.</s><s>Early EBV-disease after transplantation is extremely rare.</s><s>Primary or secondary prophylactic use of antiviral agents is not effective against EBV and therefore not recommended (DII) <ref type="bibr" target="#b116">[193,</ref><ref type="bibr" target="#b117">194]</ref>.</s><s>Close EBV viral load monitoring and rituximab application can be considered as a preemptive therapeutic approach for the prevention of EBV-associated PTLD after allo-HCT in special high-risk patients (CIII) <ref type="bibr" target="#b118">[195]</ref><ref type="bibr" target="#b119">[196]</ref><ref type="bibr" target="#b120">[197]</ref>.</s><s>Still considered experimental is the application of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients <ref type="bibr" target="#b121">[198,</ref><ref type="bibr" target="#b122">199]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxoplasmosis prophylaxis</head><p><s>Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis, administered to most transplant patients to prevent Pneumocystis jirovecii pneumonia, is also efficacious in preventing toxoplasmosis disease <ref type="bibr" target="#b123">[200,</ref><ref type="bibr" target="#b124">201]</ref>.</s><s>Clinical reactivation of toxoplasmosis may occur in the late phase after transplantation in seropositive patients under immunosuppression.</s><s>However, the risk is considerably low and no primary prophylaxis is recommended (DIII) <ref type="bibr" target="#b8">[47,</ref><ref type="bibr" target="#b125">202,</ref><ref type="bibr" target="#b126">203]</ref>.</s><s>After a successful therapy of toxoplasmosis, secondary prophylaxis should be administered for at least 3 months (AII t ) <ref type="bibr" target="#b127">[204]</ref><ref type="bibr" target="#b128">[205]</ref><ref type="bibr" target="#b129">[206]</ref> (Table <ref type="table" target="#tab_3">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hepatitis A prevention</head><p><s>The incidence of infections due to hepatitis A varies widely.</s><s>Prevention of hepatitis A by vaccination of seronegative patients or donors follows general vaccination recommendations.</s><s>A previous exposure to hepatitis A has no impact on transplant-related complications, thus only serologic testing is recommended.</s><s>In case of IgM seropositivity of the donor and/ or recipient, allo-HCT might be postponed since a high risk of transmission or hepatic complications are associated with acute hepatitis A. Additional prevention of infection of the recipient can be achieved by avoiding potentially contaminated food.</s><s>If exposed, passive immunization has been discussed controversially even in non-transplant patients.</s></p><p><s>Following patients' post allo-HCT, a continuous loss of acquired hepatitis A antibodies has been described over a median time of 48 months, especially in those older than 18 years.</s><s>Thus, hepatitis A vaccination should be recommended later in adult transplanted patients at risk (BII t ) <ref type="bibr" target="#b130">[207]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hepatitis B prevention (Table 3)</head><p><s>Hepatitis B infection or reactivation contributes to liver-related morbidity and mortality.</s><s>This is a frequent problem, which occurs in 21-53 % of patients with immunosuppression <ref type="bibr" target="#b131">[208]</ref>, In patients intolerant to conventional toxoplasmic encephalitis therapies <ref type="bibr" target="#b129">[206]</ref> a Should be combined with folinic acid especially after conditioning regimens containing alemtuzumab <ref type="bibr" target="#b132">[209]</ref>.</s><s>The goal is to avoid impairment of liver function, fulminant liver failure, hepatic sinusoidal obstruction syndrome (SOS), cirrhosis, or even hepatocellular cancer <ref type="bibr" target="#b133">[210]</ref>.</s><s>Preferably, HBsAG-negative donors should be selected.</s><s>However, if no other HLA-compatible donor is available, a positive donor for transplantation is not absolutely contraindicated (BIII).</s><s>Although transplantation of HBV-negative patient with stem cells from an infected donor (HBsAG positive) is associated with a high risk of transmission, some patients develop chronic hepatitis B <ref type="bibr" target="#b133">[210]</ref>.</s><s>Donors with active HBV (DNA detection) should receive antiviral treatment, if possible (AIII).</s></p><p><s>All HBsAG-positive patients awaiting chemotherapy or immunosuppressive therapy should receive antiviral prophylaxis with a nucleoside analogue, regardless of HBV-DNA levels.</s><s>In anti-HBc positive patients with no detectable viral replication (resolved HBV infection), there is a serious risk (up to 50 %) of reverse seroconversion after allo-HCT <ref type="bibr" target="#b134">[211]</ref>.</s><s>These patients should be monitored for HBV replication on a regular basis and receive preemptive antiviral treatment with lamivudine (AII) or entecavir (AII) once HBV DNA levels are positive (more details: Table <ref type="table" target="#tab_2">3</ref>).</s><s>It is recommended that antiviral treatment should be continued until at least 6 months after the cessation of immunosuppression (BIII) <ref type="bibr">[29]</ref>.</s><s>Prophylactic treatment of anti-HBc-positive patients without any viral load during the first months after allo-HCT is optional since no data are published in this patient population (CIII).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hepatitis C prevention</head><p><s>Patients tested positive for HCV-RNA have a significantly higher risk of developing sinusoidal obstruction syndrome (SOS).</s><s>Long after allo-HCT they suffer a higher rate of liver fibrosis or cirrhosis <ref type="bibr">[34]</ref>.</s><s>Therefore, patients tested positive for HCV-RNA should be considered (if time permitted) to receive highly active antiviral treatment (BII t ) <ref type="bibr" target="#b135">[212]</ref>.</s><s>In allo-HCT, data is lacking; however, Mahale et al. reported that patients who have successfully eliminated HCV are not at risk of reactivation at least after conventional chemotherapy <ref type="bibr" target="#b135">[212]</ref>.</s><s>Detailed therapy recommendations cannot be provided since at this time many promising trials with new drugs are being published demonstrating eradication of HCV <ref type="bibr" target="#b136">[213]</ref>.</s></p><p><s>Allo-HCT from an HCV-RNA-positive donor should be avoided since the incidence of transmission remains high (DII).</s><s>If timing permitted and no alternative donor options are available, the donor should be treated accordingly to prevent hepatic complications (AII t ) [214].</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prevention of diseases caused by respiratory viruses</head><p><s>In recent years, an increasing number of reports on respiratory viral infections after allo-HCT are noted, which are in part attributable to improved diagnostic tools and better awareness.</s></p><p><s>RSV followed by influenza, parainfluenza, metapneumovirus, and adenovirus are the main viruses causing severe diseases <ref type="bibr" target="#b138">[215]</ref>.</s><s>These viruses can contribute significantly to morbidity after allo-HCT; however, mortality rates seem to be mixed due to heterogeneity of various risk situations <ref type="bibr" target="#b139">[216]</ref>.</s><s>The main recommendation is to avoid infections with these viruses through adequate exposure prevention (AIII) <ref type="bibr" target="#b140">[217,</ref><ref type="bibr" target="#b141">218]</ref>.</s><s>Visitors and staff with signs and symptoms of respiratory infections must avoid visiting the wards to prevent further disease (AIII).</s><s>Additionally, annual influenza vaccination is strongly recommended for healthcare workers, all persons living with allo-HCT candidates or patients to prevent transmission (AIII) <ref type="bibr" target="#b142">[219]</ref>.</s><s>If vaccination was carried out during an influenza outbreak, a 2-week course of antiviral chemoprophylaxis could follow until immune response is effective (BIII) <ref type="bibr">[19,</ref><ref type="bibr" target="#b143">220]</ref>.</s></p><p><s>There is no published data confirming clinical efficacy of prophylactic administration of respiratory syncytial virus (RSV) immune globulin (RSVIG); therefore, this approach is discouraged (DII) <ref type="bibr" target="#b144">[221]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intravenous immune globulin for prophylaxis</head><p><s>There is an ongoing controversy about the benefit, dosing, and optimum preparation (hyperimmune or polyvalent) of intravenous immune globulins (IVIG) in allo-HCT <ref type="bibr" target="#b145">[222]</ref>.</s><s>Older studies have demonstrated prevention of infection, interstitial pneumonia (IP), or GVHD <ref type="bibr" target="#b146">[223,</ref><ref type="bibr" target="#b147">224]</ref>.</s><s>Large meta-analyses demonstrated no clinical benefit, except for a decrease of IP and an increase of sinusoidal obstruction syndrome (SOS) with high-dose IVIG <ref type="bibr" target="#b148">[225,</ref><ref type="bibr" target="#b149">226]</ref>.</s></p><p><s>In a recent multicenter trial, 200 patients received different doses of IVIG or placebo weekly starting day −7 till day +100, but no differences were observed in regards to infections, interstitial pneumonia, treatment-related mortality, and overall survival.</s><s>However, higher doses of immune globulin were again associated with deleterious SOS <ref type="bibr" target="#b150">[227]</ref>.</s><s>Therefore, the routine prophylactic substitution of immune globulin is not recommended if the IgG level is &gt;4 g/L (DI) <ref type="bibr" target="#b150">[227,</ref><ref type="bibr" target="#b151">228]</ref>.</s></p><p><s>Nevertheless, a retrospective study reported patients with severe hypogammaglobulinemia (e.g.</s><s>IgG &lt;4 g/L) were to be at risk for decreased survival <ref type="bibr" target="#b152">[229]</ref>.</s><s>This compares well with the IgG substitution recommendations by the IDSA <ref type="bibr" target="#b143">[220]</ref> and the guidelines for patients with the common variable immunodeficiency (CVID) syndrome to substitute low-dose immune globulin if IgG &lt;4 g/l <ref type="bibr" target="#b153">[230]</ref>.</s><s>According to an analysis by the Cochrane group, the use of IVIG may be considered in patients with hypogammaglobulinemia associated with CLL or multiple myeloma and recurrent infections.</s><s>IVIG can significantly decrease the number of infections <ref type="bibr" target="#b148">[225,</ref><ref type="bibr" target="#b149">226]</ref>.</s></p><p><s>Therefore, immune globulin should be replaced in patients with low serum IgG levels and recurrent infections associated with hypogammaglobulinemia to lower the incidence of infections (BII t ).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Granulocyte transfusion for prophylaxis</head><p><s>A small matched pair analysis of nine neutropenic patients at high risk for recurrence of a previous fungal infections after allo-HCT demonstrated that prophylactic administration of granulocyte transfusions could reduce the incidence and shorten the duration of fever as well as the duration of neutropenia compared to the control group <ref type="bibr" target="#b154">[231]</ref>.</s><s>Oza et al. performed a Bbiological randomization^in 151 stem cell recipients dependent on ABO-and CMV-compatibility of their donor.</s><s>There was a significant decrease in the number of febrile days and the use of intravenous antibiotics; however, no difference in the length of hospital stay or 100-day survival was noted <ref type="bibr" target="#b155">[232]</ref>.</s><s>So far, prophylactic granulocyte transfusion remains an experimental approach and is considered more a therapeutic option.</s></p><p><s>Immunization (Tables <ref type="table" target="#tab_5">5 and 6</ref>)</s></p><p><s>Protection against vaccine-preventable infections should be a part of the post-transplantation medical care management.</s><s>Ideally, trials should provide evidence for the protection against diseases.</s><s>However, a study powered for protective efficacy is not necessary if a sponsor of a vaccine study can justify the use of immunological data to predict protection against infection <ref type="bibr" target="#b156">[233]</ref>.</s><s>If it is not feasible to perform an efficacy study and there is no immunological correlation of protection, it may sometimes be justifiable to gauge the likely efficacy of a vaccine by comparison of immunological responses with those seen in past studies of similar vaccines with proven protective efficacy (e.g., acellular pertussis vaccines) <ref type="bibr" target="#b156">[233]</ref>.</s></p><p><s>In allo-HCT recipients, antibody titers against vaccinepreventable infections decline, leading to an increased risk of developing a disease <ref type="bibr" target="#b182">[259]</ref>.</s><s>For this reason, an early vaccination schedule would be warranted.</s><s>However, during the first 3 to 6 months after transplantation, a sufficient specific immune system response to vaccination cannot be expected <ref type="bibr" target="#b182">[259]</ref>.</s><s>Depending on different factors such as pre-and posttransplant treatment, age, type of transplantation, or presence of chronic GVHD, recovery of the immune system is delayed <ref type="bibr" target="#b182">[259]</ref>.</s><s>Additionally, limited information about vaccine response exists for patients after reduced-intensity conditioning or with umbilical cord blood grafts.</s><s>Administration of rituximab can suppress humoral immune response as long as 6 months after the last dose.</s><s>Delayed vaccination schedules should be considered in these patients (BII t ) <ref type="bibr" target="#b183">[260]</ref><ref type="bibr" target="#b184">[261]</ref><ref type="bibr" target="#b185">[262]</ref>.</s><s>Pneumococcal and meningococcal immunization with the conjugated vaccine seems to provide a more stable immune response than the polysaccharide-based vaccine in immature or altered immune systems, but comparative trials are still missing <ref type="bibr" target="#b186">[263]</ref>.</s></p><p><s>MMR (measles, mumps, rubella) and Varicella vaccines are live attenuated vaccines that should not be given within the first 2 years after transplantation or during active GVHD (DIII).</s><s>A significant risk of disease and side effects in the immunocompromised patient were observed.</s><s>However, 24 months after transplantation without evidence of chronic GVHD and immunosuppression, MMR vaccine appears safe to be administered (BIII).</s></p><p><s>Routine VZV-vaccination is currently not indicated in seropositive patients for the prevention of herpes zoster (DIII).</s><s>A newer inactivated VZV vaccine is being developed providing adequate VZV-specific antibody titers in most patients <ref type="bibr" target="#b187">[264]</ref>.</s><s>This new vaccine has the potential to change this recommendation in the future.</s></p><p><s>Additional immunizations against hepatitis A virus, human papillomavirus, yellow fever, cholera, typhus, rotavirus, or pre-exposure rabies virus vaccination are not routinely indicated in adults.</s><s>Decision-making should follow the recommendations of general population and country-specific policy.</s><s>Degree of immune suppression against live attenuated vaccines especially in the allo-HCT population needs special attention.</s></p><p><s>Little is known whether vaccinations can induce GVHD, since viral infections are known to do so <ref type="bibr" target="#b188">[265]</ref>.</s><s>On the other hand, clinical data demonstrate response to vaccination despite GVHD <ref type="bibr" target="#b189">[266,</ref><ref type="bibr" target="#b190">267]</ref>.</s><s>A group of European experts published results of a consensus conference on vaccination in GVHD <ref type="bibr" target="#b191">[268]</ref>.</s><s>The conference attendees were more cautious about immune suppression.</s><s>In patients receiving prednisone ≥0.5 mg/kg bodyweight per day as part of a combination therapy or a three-agent immunosuppressive treatment is given; vaccination may be postponed until immunosuppression is reduced to a double combination or prednisone &lt;0.5 mg/ kg bodyweight daily in order to achieve a better vaccine response (BIII) <ref type="bibr" target="#b191">[268]</ref>.</s></p><p><s>Antibody titer testing prior to and after immunization can be recommended for many vaccines.</s><s>Decision-making based on a titer is not recommended for all vaccinations to document efficacy except for VZV, HAV, or HBV.</s><s>Basically, titer determination provides some insight on vaccination success and should be considered as optional (CIII).</s><s>Testing for sufficient antibody response after immunization is indicated in hepatitis B one month or later after the third vaccine dose (BIII).</s><s>Revaccination with a second series of hepatitis B vaccine should be considered in non-responders (CIII).</s></p><p><s>In review of the available literature, clearly more studies are needed to provide more information on the safety and efficacy of vaccination schedules in allo-HCT.</s></p><p><s>Compliance with ethical standards Funding source DGHO (German Society for Hematology and Medical Oncology) Conflict of interest AJU has received support for travel to meetings from Astellas and Basilea.</s><s>He is a consultant and on the speakers' bureaus of Astellas, Gilead, MSD, and Pfizer.</s><s>He has also received support for travel and accommodation from Astellas, Boehringer Ingelheim, Gilead, MSD, and Pfizer for activities unrelated to the current study.</s><s>His institution has received grants from Astellas, Gilead, MSD, and Pfizer.</s></p><p><s>MSH: none reported.</s><s>HB has received support for travel, accommodation, and research grants from Gilead and was an advisor to Gilead.</s></p><p><s>WJH received research grants from Merck and Pfizer; serves on the speakers bureaus of Alexion, Astellas, Bristol-Myers Squibb, Chugai Pharma, Gilead, Janssen, MSD/Merck, and Pfizer; and received travel grants from Alexion, Astellas, MSD/Merck, Novartis, and Pfizer.</s></p><p><s>MK is a consultant and on the speakers' bureaus of MSD, and he is a consultant for Gilead and on the speakers' bureau of Astellas.</s></p><p><s>WK: none reported.</s><s>SM: none reported.</s><s>SN has received support for travel and accommodation from Celgene, Novartis, and Pfizer for activities unrelated to the current manuscript.</s></p><p><s>SN: none reported.</s><s>OP has received support for travel to meetings from Gilead, MSD, Jazz, and Neovii.</s><s>He is a consultant of MSD.</s><s>He has also received research support from Jazz, Neovii, Sanofi, and Takeda GS: none with regards to the guideline; consultant and speakers' bureaus for MSD, Pfizer, and Gilead; travel grants from Astellas, Gilead, MSD, Pfizer, and Roche unrelated to this manuscript.</s></p><p><s>JJV is supported by the German Federal Ministry of Research and Education (BMBF grant 01KI0771) and the German Centre for Infection Research, has received research grants from Astellas, Gilead Sciences, Infectopharm, Pfizer, and Essex/Schering-Plough; and served on the speakers' bureau of Astellas, Merck Sharp Dohme/Merck, Gilead Sciences, Pfizer, and Essex/Schering-Plough.</s></p><p><s>HE: none reported.</s><s>GM: received honorarium from Gilead, Pfizer, Astellas, Boehringer Ingelheim, Bristol-Myers Squibb and Merck-Serono.</s><s>He was also a consultant to Gilead and T2G.</s><s>He has received support for travel from Pfizer, Roche, Amgen, and Mundipharma.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Open Access</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>( D I I I ) .</s><s>(h t t p : / / w w w .</s><s>b f a r m .</s><s>d e / S h a r e d D o c s / Risikoinformationen/Pharmakovigilanz/EN/RHB/2012/rhbzostex.html, last accessed May 1, 2016)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Strength</s></p></div></figDesc><table><row><cell>of the AGIHO</cell><cell></cell><cell></cell></row><row><cell>(DGHO) and DAG-KBT</cell><cell>Strength of a recommendation</cell><cell></cell></row><row><cell>recommendation and quality of</cell><cell>Grade A</cell><cell>AGIHO strongly supports a recommendation for use</cell></row><row><cell>evidence (modified according to [4])</cell><cell>Grade B Grade C</cell><cell>AGIHO moderately supports a recommendation for use AGIHO marginally supports a recommendation for use</cell></row><row><cell></cell><cell>Grade D</cell><cell>AGIHO supports a recommendation against use</cell></row><row><cell></cell><cell>Quality of evidence</cell><cell></cell></row><row><cell></cell><cell>Level I</cell><cell>Evidence from at least 1 properly designed randomized, controlled trial</cell></row><row><cell></cell><cell>Level II a</cell><cell>Evidence from at least 1 well-designed clinical trial, without</cell></row><row><cell></cell><cell></cell><cell>randomization; from cohort or case-controlled analytic studies</cell></row><row><cell></cell><cell></cell><cell>(preferably from &gt;1 centre); from multiple time series; or from</cell></row><row><cell></cell><cell></cell><cell>dramatic results of uncontrolled experiments</cell></row><row><cell></cell><cell>Level III</cell><cell>Evidence from opinions of respected authorities, based on clinical</cell></row><row><cell></cell><cell></cell><cell>experience, descriptive case studies</cell></row></table><note><p><s>a Added index: r : meta-analysis (or systematic review of RCT); t : transferred evidence i.e., results from different patients 'cohorts' or similar immune status situation; h : comparator group: historical control; u : uncontrolled trials;</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Antifungal prophylaxis</s></p></div></figDesc><table><row><cell>Intention</cell><cell>Intervention</cell><cell cols="3">SoR QoE Comments</cell><cell>Ref</cell></row><row><cell>Prevent mould infection in</cell><cell>Voriconazole 200 mg bid</cell><cell>C</cell><cell>I</cell><cell>No difference seen in the trial in</cell><cell>[114]</cell></row><row><cell>patients without GvHD, day 1-100</cell><cell>oral or iv b</cell><cell></cell><cell></cell><cell>comparison to fluconazole</cell><cell></cell></row><row><cell></cell><cell>Posaconazole (suspension) 200 mg tid b</cell><cell>B</cell><cell>II t</cell><cell>induction during neutropenia, new Improved overall survival in AML/MDS</cell><cell>[115-117]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>formulations (tablet and iv, 300 mg qid)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>provide a better bioavailability</cell><cell></cell></row><row><cell></cell><cell>Micafungin 50 mg/day</cell><cell>C</cell><cell>I</cell><cell>Only during neutropenia, morbidity advantage</cell><cell>[118]</cell></row><row><cell></cell><cell>Itraconazole suspension</cell><cell>C</cell><cell>I</cell><cell>Administered up to 180 days if GVHD was</cell><cell>[119-121]</cell></row><row><cell></cell><cell>2.5-7.5 mg/kg or capsules</cell><cell></cell><cell></cell><cell>diagnosed; higher toxicity in comparison</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>to fluconazole, TDM: cutoff at 500 mg/mL (AII)</cell><cell></cell></row><row><cell>Prevent invasive Candida</cell><cell>Fluconazole 400 mg/day</cell><cell>A</cell><cell>I</cell><cell>Improved survival, note rising incidence of</cell><cell>[122-124]</cell></row><row><cell>disease in patients without</cell><cell></cell><cell></cell><cell></cell><cell>resistant Candida species since studies</cell><cell></cell></row><row><cell>GvHD, day 1-100</cell><cell></cell><cell></cell><cell></cell><cell>were published</cell><cell></cell></row><row><cell></cell><cell>Voriconazole 200 mg bid oral or iv b</cell><cell>B</cell><cell>II t</cell><cell>seen in the trial between voriconazole and Also active against moulds, but no difference</cell><cell>[114]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>fluconazole</cell><cell></cell></row><row><cell></cell><cell>Posaconazole (suspension) 200 mg tid b</cell><cell>B</cell><cell>II t</cell><cell>(tablet and iv, 300 mg qd) provide a better Also effective against moulds, new formulations</cell><cell>[115, 117]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>bioavailability</cell><cell></cell></row><row><cell></cell><cell>Micafungin 50 mg/day</cell><cell>B</cell><cell>II t</cell><cell>Also effective against moulds, only during</cell><cell>[118]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>neutropenia, morbidity advantage</cell><cell></cell></row><row><cell></cell><cell>Itraconazole suspension</cell><cell>C</cell><cell>I</cell><cell>See above</cell><cell>[119-121]</cell></row><row><cell></cell><cell>2.5-7.5 mg/kg or capsules b</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prevent invasive Aspergillosis</cell><cell>Posaconazole (suspension)</cell><cell>A</cell><cell>I</cell><cell>improved survival (lower attributable mortality),</cell><cell>[117, 125]</cell></row><row><cell>during GvHD</cell><cell>200 mg tid b</cell><cell></cell><cell></cell><cell>new formulations (tablet and iv, 300 mg qd)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>provide a better bioavailability</cell><cell></cell></row><row><cell>Prevent fungal disease relapse</cell><cell>Voriconazole b</cell><cell>B</cell><cell>II</cell><cell>considered as secondary antifungal prophylaxis,</cell><cell>[126]</cell></row><row><cell>(previous IFD)</cell><cell>Caspofungin, posaconazole</cell><cell>B</cell><cell>III</cell><cell>dosages as above</cell><cell>[127, 128]</cell></row><row><cell>Prevent fungal diseases a</cell><cell cols="2">Amphotericin B deoxycholate D</cell><cell>II</cell><cell>Inacceptable toxicity</cell><cell>[129-131]</cell></row></table><note><p><s>a other formulations and various dosages and application regimens of Amphotericin B have been evaluated with different results in small studies, all would need further evaluation to provide any kind of recommendation [132-134] b Consider TDM, serum levels of efficacy in prophylaxis are still debated, e.g.posaconazole[135]</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Antiviral prophylaxis</s></p></div></figDesc><table><row><cell>Intention</cell><cell>Intervention</cell><cell cols="3">SoR QoE Comments</cell><cell>Ref</cell></row><row><cell>HSV</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prevent HSV disease</cell><cell>Acyclovir 400 mg tid/day</cell><cell>A</cell><cell>II</cell><cell>Up to 30 days post allo-HCT</cell><cell>[139, 141,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(various dosages)</cell><cell>233]</cell></row><row><cell></cell><cell>Valacyclovir 500 mg bid /day</cell><cell>A</cell><cell>II</cell><cell></cell><cell>[234]</cell></row><row><cell></cell><cell>Acyclovir any dosage</cell><cell>D</cell><cell>III</cell><cell>Beyond 30 days if patient is</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>also VZV seronegative</cell><cell></cell></row><row><cell>VZV</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>VZV disease prevention in</cell><cell>Acyclovir 800 mg bid</cell><cell>A</cell><cell>I</cell><cell>Up to 1 year after allo-HCT</cell><cell>[156]</cell></row><row><cell>VZV seropositive recipients</cell><cell>Acyclovir 400 mg/day</cell><cell>B</cell><cell>II</cell><cell></cell><cell>[158, 159,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>235]</cell></row><row><cell></cell><cell>Valacyclovir 500 mg bid</cell><cell>B</cell><cell>II</cell><cell></cell><cell>[236, 237]</cell></row><row><cell></cell><cell>Acyclovir 200 mg/day</cell><cell>B</cell><cell>II</cell><cell>More than 365 days if continued on</cell><cell>[233, 238]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>immunosuppressive therapy</cell><cell></cell></row><row><cell>Prevent VZV in seronegative patients</cell><cell>No prophylaxis</cell><cell>C</cell><cell>III</cell><cell></cell><cell></cell></row><row><cell>Prevent VZV in seronegative</cell><cell>Passive immunization</cell><cell>C</cell><cell>II t</cell><cell cols="2">Within 96 h post exposure, optional [155]</cell></row><row><cell>patients if exposed</cell><cell>Acyclovir or other VZV-active an-</cell><cell>C</cell><cell>III</cell><cell>If patient is not on acyclovir</cell><cell></cell></row><row><cell></cell><cell>tiviral</cell><cell></cell><cell></cell><cell>(or any other VZV active</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>antiviral), a short duration of</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>therapy is an option.</cell><cell></cell></row><row><cell>Prevent VZV disease after exposure</cell><cell>Vaccination</cell><cell>-</cell><cell>-</cell><cell>No data to provide recommendation</cell><cell></cell></row><row><cell>CMV</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Preemptive strategy recommended</cell><cell>Ganciclovir, valganciclovir,</cell><cell>A</cell><cell>I</cell><cell></cell><cell>[177,</cell></row><row><cell>over prophylaxis/treatment</cell><cell>or foscarnet</cell><cell></cell><cell></cell><cell></cell><cell>239-242]</cell></row><row><cell>Reduce incidence of CMV infection/</cell><cell cols="2">Long term acyclovir 800 mg/day C</cell><cell>II</cell><cell></cell><cell>[180]</cell></row><row><cell>disease, if a center does not follow a preemptive strategy</cell><cell cols="2">Valacyclovir 500 mg qid/day Ganciclovir 2.5-5 mg/kg bid/day C B</cell><cell>I II</cell><cell>Caution: myelotoxicity</cell><cell>[182] [243, 244]</cell></row><row><cell></cell><cell>Valganciclovir 900 mg bid</cell><cell>A</cell><cell>II</cell><cell>Caution: myelotoxicity</cell><cell>[177]</cell></row><row><cell></cell><cell>CMV-specific CTLs</cell><cell>C</cell><cell>II</cell><cell>Not available at every site</cell><cell>[245]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(considered experimental)</cell><cell></cell></row><row><cell>HBV</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prevent disease in HBsAG</cell><cell>Lamivudine 100 mg/day</cell><cell>A</cell><cell>II</cell><cell>Monitor HBV DNA closely, duration</cell><cell>[210, 246,</cell></row><row><cell>seropositive recipients</cell><cell></cell><cell></cell><cell></cell><cell>until anti-HBs is detected</cell><cell>247]</cell></row><row><cell></cell><cell>Entecavir 0.5-1.0 mg/day</cell><cell>A</cell><cell>II</cell><cell>(and HBV-DNA is negative)</cell><cell>[248-250]</cell></row><row><cell></cell><cell>Tenofovir 245 mg/day</cell><cell>C</cell><cell>III</cell><cell></cell><cell>[251, 252]</cell></row><row><cell>Prevent disease in HBsAG seropositive</cell><cell>Additionally vaccinate donor</cell><cell>B</cell><cell>III</cell><cell>Requires long term planning</cell><cell>[253]</cell></row><row><cell>recipients with HBsAG seronegative donors</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prevent reactivation in recipients who are</cell><cell>Lamivudine 100 mg/day</cell><cell>B</cell><cell>III</cell><cell></cell><cell>[209]</cell></row><row><cell>anti-HBcAG seropositive, DNA viral load:</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>positive</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prevent reactivation and disease in recipients</cell><cell>Lamivudine 100 mg/day</cell><cell>C</cell><cell>III</cell><cell></cell><cell></cell></row><row><cell>who are anti-HBcAG seropositive, DNA viral load: negative</cell><cell cols="2">HBV-DNA/HBsAG monitoring B</cell><cell>III</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Secondary prophylaxis after toxoplasmosis disease</s></p></div></figDesc><table><row><cell>Intention</cell><cell>Intervention</cell><cell>SoR</cell><cell>QoE</cell><cell>Comments</cell><cell>Ref</cell></row><row><cell>To prevent relapse</cell><cell>Pyrimethamine (25 mg/day) a +</cell><cell>A</cell><cell>I I t</cell><cell>Minimum duration for 3 months,</cell><cell>[204, 206]</cell></row><row><cell>of CNS toxoplasmosis</cell><cell>sulfadiazine (orally, 30 mg/kg/d)</cell><cell></cell><cell></cell><cell>many cases longer</cell><cell></cell></row><row><cell></cell><cell>Pyrimethamine (25 mg/d) a + clindamycin</cell><cell>B</cell><cell>I I t</cell><cell></cell><cell>[255-257]</cell></row><row><cell></cell><cell>(intravenously, 1200 mg/d)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Atovaquone 750 mg qid</cell><cell>B</cell><cell>II t</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5</head><label>5</label><figDesc><div><p><s>Vaccination recommendations for allo-HCT recipients</s></p></div></figDesc><table><row><cell>Ref</cell><cell></cell><cell></cell><cell>[258, 269-270, 310]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>[266, 271-276]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>[276-278]</cell><cell>[279-281, 310]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>[282]</cell><cell></cell><cell>[281, 283-288]</cell><cell>[269, 288-295, 310]</cell><cell></cell><cell>[295-297]</cell><cell></cell><cell></cell><cell></cell><cell>[33, 207, 298-300]</cell><cell></cell><cell></cell><cell></cell><cell>[301-303]</cell><cell></cell><cell></cell><cell>[304-307]</cell></row><row><cell>Comments</cell><cell></cell><cell></cell><cell>Post allo-HCT 6 months; 3 applications of</cell><cell>13-valent pneumococcal conjugate vaccine</cell><cell>(PCV13, 4 weeks apart).</cell><cell>After 1 year post allo-HCT use 23-valent</cell><cell>polysaccharide pneumococcal vaccine;</cell><cell>no data for non-myeloablative,</cell><cell>haplo-identical, or DLI protocol regimes</cell><cell>Alone not recommended as a single vaccine</cell><cell>since conjugate vaccine provide a better</cell><cell>immune response</cell><cell>Consider to vaccinate patient after 4 weeks</cell><cell>again (BII) if still early after transplantation;</cell><cell>Include next of kin and healthcare workers</cell><cell>(HCW) to receive vaccination as well (AIII).</cell><cell>Consider quadrivalent vaccine (BIII).</cell><cell>Antibody levels do not reflect effective vaccination.</cell><cell>First diphtheria and tetanus vaccination</cell><cell>after 12 months; only data available</cell><cell>beyond 12 months; for diphtheria</cell><cell>higher dose possibly better (child dosage)</cell><cell>but not approved (BIII)</cell><cell>Only in endemic areas</cell><cell></cell><cell>Inactivated vaccine only</cell><cell>Incidence of HI type B (vs. non type B)</cell><cell>infections after allo-HCT is relatively low.</cell><cell>Europe, North America and Canada register</cell><cell>high rates of meningococcal disease by</cell><cell>serogroup B. Therefore, both vaccines are</cell><cell>recommended equally.</cell><cell>Only in patients at risk for hepatitis.</cell><cell>Combination vaccination possible. Patients</cell><cell>with a previous history of HBV need to</cell><cell>be revaccinated (AII).</cell><cell>Live attenuated vaccine after 24 months post</cell><cell>allo-HCT and no GVHD or immunosuppressive</cell><cell>therapy. Less than 24 months: DIII.</cell><cell>Consider occupational risks and household.</cell><cell>As MMR but no history of VZV</cell><cell>disease and seronegative</cell></row><row><cell>QoE</cell><cell></cell><cell></cell><cell>I I t</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>II</cell><cell></cell><cell></cell><cell>II</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>III</cell><cell>II</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">II t</cell><cell>II</cell><cell>II</cell><cell></cell><cell>I I t</cell><cell></cell><cell></cell><cell></cell><cell>I I t</cell><cell></cell><cell></cell><cell></cell><cell>II</cell><cell></cell><cell></cell><cell>II</cell></row><row><cell>SoR</cell><cell></cell><cell></cell><cell>A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>D</cell><cell></cell><cell></cell><cell>A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>A</cell><cell>A</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>B</cell><cell></cell><cell>A</cell><cell>B</cell><cell></cell><cell>B</cell><cell></cell><cell></cell><cell></cell><cell>B</cell><cell></cell><cell></cell><cell></cell><cell>B</cell><cell></cell><cell></cell><cell>B</cell></row><row><cell></cell><cell>after</cell><cell>24 months</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>X</cell><cell></cell><cell></cell><cell>X</cell></row><row><cell></cell><cell>after 6-</cell><cell>12 months</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(X)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>X</cell><cell>X</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>X</cell><cell></cell><cell>X</cell><cell>X</cell><cell></cell><cell>X</cell><cell></cell><cell></cell><cell></cell><cell>X</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Intervention (timing of 1st application after allo-HCT)</cell><cell>after day</cell><cell>+100</cell><cell>X Pneumococcus (combination</cell><cell>of conjugate and</cell><cell>polysaccharide vaccines)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Pneumococcus (polysaccharide</cell><cell>vaccine) 23-valent (PPV23)</cell><cell></cell><cell>X Influenza</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Bordatella pertussis (acellular) b</cell><cell>Diphtheria and tetanus toxoid a, b</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>TBE a (Tick-borne encephalitis)</cell><cell cols="2">Poliovirus a, b</cell><cell>Haemophilus influenza (HI) a, b</cell><cell></cell><cell>Meningococcal conjugate vaccine</cell><cell>against serogroups A, C, W135,</cell><cell>Y and Meningococcal vaccine</cell><cell>for serogroup B</cell><cell>Hepatitis A and B (HAV and HBV) a, b</cell><cell></cell><cell></cell><cell></cell><cell>MMR (mumps, measles, and</cell><cell>rubella; life attenuated vaccine) a, b</cell><cell></cell><cell>VZV (varizella zoster virus, life</cell><cell>attenuated vaccine) a</cell></row><row><cell>Intention</cell><cell>Vaccine</cell><cell></cell><cell>Provide immunity</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>a Consider antibody measurements b Consider combination vaccines</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 6</head><label>6</label><figDesc><div><p><s>Immunization schedule</s></p></div></figDesc><table><row><cell>Vaccine</cell><cell>SoR/</cell><cell cols="4">Relative to day of allo-HCT</cell><cell>12 months</cell><cell>Refresher</cell><cell>Comments</cell><cell>Ref</cell></row><row><cell></cell><cell>QoE</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>after first</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>Day</cell><cell>Month</cell><cell>Month</cell><cell>Month</cell><cell>vaccination</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>+100</cell><cell>+6</cell><cell>+7</cell><cell>+8</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Pneumococcus AII t X</cell><cell>X</cell><cell>X</cell><cell></cell><cell>X</cell><cell>Unclear</cell><cell>Start with PCV13, after</cell><cell>[269-270, 308]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>12 months after first</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>vaccination the 23</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>valent polysaccharide</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>vaccine should be</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>used</cell></row><row><cell>Influenza</cell><cell>AII</cell><cell>X</cell><cell></cell><cell></cell><cell></cell><cell>X</cell><cell>Annually</cell><cell></cell><cell>[266, 271-276]</cell></row><row><cell>Polio</cell><cell>AII</cell><cell></cell><cell>X</cell><cell>X</cell><cell>X</cell><cell>X</cell><cell>According to local</cell><cell>a Combination</cell><cell>[283-288, 309]</cell></row><row><cell>inactivated a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>health advisory</cell><cell>vaccine possible</cell></row><row><cell>Pertussis</cell><cell>AIII</cell><cell></cell><cell>X</cell><cell>X</cell><cell>X</cell><cell>X</cell><cell></cell><cell></cell><cell>[277, 278, 309]</cell></row><row><cell>(acellular) a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diphtheria and</cell><cell>AII</cell><cell></cell><cell>X</cell><cell>X</cell><cell>X</cell><cell>X</cell><cell></cell><cell></cell><cell>[279-282, 292, 309]</cell></row><row><cell>tetanus</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>toxoid a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Haemophilus</cell><cell>BII</cell><cell></cell><cell>X</cell><cell>X</cell><cell>X</cell><cell>X</cell><cell></cell><cell></cell><cell>[269, 284, 288-295, 311,</cell></row><row><cell>influenzae a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>312]</cell></row><row><cell>Meningococcal</cell><cell>BII</cell><cell></cell><cell>X</cell><cell></cell><cell></cell><cell>X</cell><cell>None</cell><cell></cell><cell>[295, 313-315]</cell></row><row><cell>conjugate 4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>valent and</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>serogroup B</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TBE</cell><cell>BII t</cell><cell></cell><cell>X</cell><cell>X</cell><cell></cell><cell>X</cell><cell>5 years</cell><cell></cell><cell>[282, 316]</cell></row><row><cell>Hepatitis B</cell><cell>CII</cell><cell></cell><cell>X</cell><cell></cell><cell></cell><cell>X</cell><cell>Depending on titer</cell><cell>Combination vaccine</cell><cell>[298-299, 317-320]</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>possible (together</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>with HAV)</cell></row><row><cell>Mumps,</cell><cell>BII</cell><cell cols="3">Live attenuated vaccine</cell><cell></cell><cell></cell><cell>Unclear, depending</cell><cell>One dose is</cell><cell>[301-303, 321,</cell></row><row><cell>measles,</cell><cell></cell><cell cols="3">after 24 months</cell><cell></cell><cell></cell><cell>on immune</cell><cell>recommended</cell><cell>322]</cell></row><row><cell>rubella</cell><cell></cell><cell cols="3">accordingly to the</cell><cell></cell><cell></cell><cell>response</cell><cell></cell></row><row><cell>Varicella zoster</cell><cell>BII</cell><cell cols="2">rule mentioned</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>[304-307, 323]</cell></row><row><cell>virus (VZV)</cell><cell></cell><cell cols="2">in Table 5</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>a combination vaccination possible</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head></head><label></label><figDesc><div><p><s>This article is distributed under the terms of the Creative Comm ons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/),whichpermitsunrestricted</s><s>use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Slavin MA et al(1995)Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study.J Infect Dis 171(6): 1545-1552 125.</s><s>Ullmann AJ et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.</s><s>N Engl J Med 356(4): 335-347 126.</s><s>Cordonnier C et al (2004) Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.</s><s>Bone Marrow Transplant 33(9):943-948 127.</s><s>de Fabritiis P et al (2007) Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection.</s><s>Bone Marrow Transplant 40(3):245-249 128.</s><s>Gupta S et al (2007) Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation.</s><s>Transpl Infect Dis 9(2):156-160 129.</s><s>Wingard JR et al (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.</s><s>Clin Infect Dis 29(6):1402-1407 130. Bates DW et al (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy.</s><s>Clin Infect Dis 32(5): 686-693 131.</s><s>Ullmann AJ et al (2006) Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.</s><s>Clin Infect Dis 43(4):e29-e38 132.</s><s>Penack O et al (2006) Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial.</s><s>Ann Oncol 17(8):1306-1312 133.</s><s>Behre GF et al (1995) Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients.</s><s>Ann Hematol 71(6):287-291 134.</s><s>Luu Tran H et al. (2014) Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graftversus-host disease.</s><s>J Oncol Pharm Pract 22(2):228-234 135.</s><s>Cornely OA, Ullmann AJ (2011) Lack of evidence for exposureresponse relationship in the use of posaconazole as prophylaxis against invasive fungal infections.</s><s>Clin Pharmacol Ther 89(3): 351-352 136.</s><s>Kawamura K et al (2014) Prophylactic role of long-term ultralow-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.</s><s>Int J Infect Dis 19: 26-32 137.</s><s>Meyers JD, Flournoy N, Thomas ED (1980) Infection with herpes simplex virus and cell-mediated immunity after marrow transplant.</s><s>J Infect Dis 142(3):338-346 138.</s><s>Saral R et al (1981) Acyclovir prophylaxis of herpes-simplexvirus infections.</s><s>N Engl J Med 305(2):63-67 139.</s><s>Gluckman E et al (1983) Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir.</s><s>Lancet 2(8352): 706-708 140.</s><s>Wade JC et al (1982) Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial.</s><s>Ann Intern Med 96(3):265-269 141.</s><s>Wade JC et al (1984) Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation.</s><s>Ann Intern Med 100(6):823-828 142.</s><s>Ljungman P et al (1986) Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro.</s><s>Bone Marrow Transplant 1(2):185-192 143.</s><s>Sauerbrei A et al (2011) Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antivir Ther 16(8):1297-1308 144.</s><s>McLaren C, Sibrack CD, Barry DW (1982) Spectrum of sensitivity of acyclovir of herpes simplex virus clinical isolates.</s><s>Am J Med 73(1A):376-379 145.</s><s>Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.</s><s>Antimicrob Agents Chemother 55(2):459-472 146.</s><s>Mertz GJ et al (1997) Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women.</s><s>A multicenter, double-blind, placebo-controlled trial.</s><s>Collaborative Famciclovir Genital Herpes Research Group.</s><s>Arch Intern Med 157(3):343-349 147.</s><s>Tyring SK, Baker D, Snowden W (2002) Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.</s><s>J Infect Dis 186(Suppl 1):S40-S46 148.</s><s>Garner JS (1996) Guideline for isolation precautions in hospitals.</s><s>The Hospital Infection Control Practices Advisory Committee.</s><s>Infect Control Hospital Epidemiol 17(1):53-80 149.</s><s>Josephson A, Gombert ME (1988) Airborne transmission of nosocomial varicella from localized zoster.</s><s>J Infect Dis 158(1):238-241 150.</s><s>Koc Y et al (2000) Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.</s><s>Biol Blood Marrow Transplant 6(1):44-49 151.</s><s>Rumke HC et al (2011) Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4week or a 12-month interval between two doses.</s><s>Vaccine 29(22):3842-3849 152.</s><s>Han CS et al (1994) Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications.</s><s>Bone Marrow Transplant 13(3):277-283 153.</s><s>Locksley RM et al (1985) Infection with varicella-zoster virus after marrow transplantation.</s><s>J Infect Dis 152(6):1172-1181 154.</s><s>Weinstock DM, Boeckh M, Sepkowitz KA (2006) Postexposure prophylaxis against varicella zoster virus infection among</s></p></div></figDesc><table><row><cell cols="2">(AGIHO) of the German Society of Hematology and Oncology 115. Cornely OA et al (2007) Posaconazole vs. fluconazole or</cell><cell>23. Kelsey SM, Newland AC (1989) Cytomegalovirus seroconver-</cell></row><row><cell></cell><cell>(DGHO). Ann Hematol 82(Suppl 2):S175-S185 itraconazole prophylaxis in patients with neutropenia. N Engl J</cell><cell>sion in patients receiving intensive induction therapy prior to al-</cell></row><row><cell cols="2">4. Ullmann AJ et al (2012) ESCMID* guideline for the diagnosis Med 356(4):348-359</cell><cell>logeneic bone marrow transplantation. Bone Marrow Transplant</cell></row><row><cell cols="2">and management of Candida diseases 2012: developing European 116. Duarte RF et al (2014) Phase 1b study of new posaconazole tablet</cell><cell>4(5):543-546</cell></row><row><cell></cell><cell>guidelines in clinical microbiology and infectious diseases. Clin for prevention of invasive fungal infections in high-risk patients with</cell><cell>24. Hamadani M et al (2010) How we approach patient evaluation for</cell></row><row><cell></cell><cell>Microbiol Infect 18(Suppl 7):1-8 neutropenia. Antimicrob Agents Chemother 58(10):5758-5765</cell><cell>hematopoietic stem cell transplantation. Bone Marrow Transplant</cell></row><row><cell cols="2">5. Cornet M et al (1999) Efficacy of prevention by high-efficiency 117. Cornely OA et al. (2016) Phase 3 pharmacokinetics and safety</cell><cell>45(8):1259-1268</cell></row><row><cell></cell><cell>particulate air filtration or laminar airflow against Aspergillus air-study of a posaconazole tablet formulation in patients at risk for</cell><cell>25. Schmidt-Hieber M et al (2013) CMV serostatus still has an impor-</cell></row><row><cell></cell><cell>borne contamination during hospital renovation. Infect Control invasive fungal disease. J Antimicrob Chemother 71(6):1747</cell><cell>tant prognostic impact in de novo acute leukemia patients after</cell></row><row><cell cols="2">Hosp Epidemiol 20(7):508-513 118. van Burik JA et al (2004) Micafungin versus fluconazole for pro-</cell><cell>allogeneic stem cell transplantation: a report from the Acute</cell></row><row><cell cols="2">6. Eckmanns T, Ruden H, Gastmeier P (2006) The influence of high-phylaxis against invasive fungal infections during neutropenia in</cell><cell>Leukemia Working Party of EBMT. Blood 122(19):3359-3364</cell></row><row><cell></cell><cell>efficiency particulate air filtration on mortality and fungal infec-patients undergoing hematopoietic stem cell transplantation. Clin</cell><cell>26. Stewart JA et al (1995) Herpesvirus infections in persons infected</cell></row><row><cell></cell><cell>tion among highly immunosuppressed patients: a systematic re-Infect Dis 39(10):1407-1416</cell><cell>with human immunodeficiency virus. Clin Infect Dis 21(Suppl 1):</cell></row><row><cell cols="2">view. J Infect Dis 193(10):1408-1418 119. Marr KA et al (2004) Itraconazole versus fluconazole for preven-</cell><cell>S114-S120</cell></row><row><cell cols="2">7. Oren I et al (2001) Invasive pulmonary aspergillosis in neutrope-tion of fungal infections in patients receiving allogeneic stem cell</cell><cell>27. Liang R, Lau GK, Kwong YL (1999) Chemotherapy and bone</cell></row><row><cell></cell><cell>nic patients during hospital construction: before and after chemo-transplants. Blood 103(4):1527-1533</cell><cell>marrow transplantation for cancer patients who are also chronic</cell></row><row><cell cols="2">prophylaxis and institution of HEPA filters. Am J Hematol 66(4): 120. Glasmacher A et al (1998) Antifungal prophylaxis with</cell><cell>hepatitis B carriers: a review of the problem. J Clin Oncol 17(1):</cell></row><row><cell></cell><cell>257-262 itraconazole in neutropenic patients with acute leukaemia.</cell><cell>394-398</cell></row><row><cell cols="2">8. Kruger WH et al (2003) Effective protection of allogeneic stem Leukemia 12(9):1338-1343</cell><cell>28. Hammond SP et al (2009) Hepatitis B virus reactivation following</cell></row><row><cell cols="2">cell recipients against Aspergillosis by HEPA air filtration during a 121. Glasmacher A et al (1999) Breakthrough invasive fungal infec-</cell><cell>allogeneic hematopoietic stem cell transplantation. Biol Blood</cell></row><row><cell></cell><cell>period of construction-a prospective survey. J Hematother Stem tions in neutropenic patients after prophylaxis with itraconazole.</cell><cell>Marrow Transplant 15(9):1049-1059</cell></row><row><cell></cell><cell>Cell Res 12(3):301-307 Mycoses 42(7-8):443-451</cell><cell>29. Liang R (2009) How I treat and monitor viral hepatitis B infection</cell></row><row><cell cols="2">9. Vokurka S et al (2014) The availability of HEPA-filtered rooms 122. Goodman JL et al (1992) A controlled trial of fluconazole to pre-</cell><cell>in patients receiving intensive immunosuppressive therapies or</cell></row><row><cell></cell><cell>and the incidence of pneumonia in patients after haematopoietic vent fungal infections in patients undergoing bone marrow trans-</cell><cell>undergoing hematopoietic stem cell transplantation. Blood</cell></row><row><cell></cell><cell>stem cell transplantation (HSCT): results from a prospective, plantation. N Engl J Med 326(13):845-851</cell><cell>113(14):3147-3153</cell></row><row><cell cols="2">multicentre, eastern European study. J Clin Nurs 23(11-12): 123. Marr KA et al (2000) Prolonged fluconazole prophylaxis is asso-</cell><cell>30. Knoll A et al (2004) Reactivation of resolved hepatitis B virus</cell></row><row><cell></cell><cell>1648-1652 ciated with persistent protection against candidiasis-related death</cell><cell>infection after allogeneic haematopoietic stem cell transplantation.</cell></row><row><cell cols="2">10. Humphreys H (2004) Positive-pressure isolation and the preven-in allogeneic marrow transplant recipients: long-term follow-up of</cell><cell>Bone Marrow Transplant 33(9):925-929</cell></row><row><cell></cell><cell>tion of invasive aspergillosis. What is the evidence? J Hosp Infect a randomized, placebo-controlled trial. Blood 96(6):2055-2061</cell><cell>31. Mikulska M et al (2014) Hepatitis B reactivation in HBsAg-neg-</cell></row><row><cell>124.</cell><cell>56(2):93-100, quiz 163</cell><cell>ative/HBcAb-positive allogeneic haematopoietic stem cell trans-</cell></row><row><cell cols="2">11. Hayes-Lattin B, Leis JF, Maziarz RT (2005) Isolation in the allo-</cell><cell>plant recipients: risk factors and outcome. Clin Microbiol Infect</cell></row><row><cell></cell><cell>geneic transplant environment: how protective is it? Bone Marrow</cell><cell>20(10):O694-O701</cell></row><row><cell></cell><cell>Transplant 36(5):373-381</cell><cell>32. Pompili M et al (2015) Prospective study of hepatitis B virus</cell></row><row><cell cols="2">12. McCann S et al (2004) Outbreaks of infectious diseases in stem</cell><cell>reactivation in patients with hematological malignancies. Ann</cell></row><row><cell></cell><cell>cell transplant units: a silent cause of death for patients and trans-</cell><cell>Hepatol 14(2):168-174</cell></row><row><cell></cell><cell>plant programmes. Bone Marrow Transplant 33(5):519-529</cell><cell>33. Takahata M et al. (2014) Hepatitis B virus (HBV) reverse sero-</cell></row><row><cell cols="2">13. Harrington RD et al (1992) An outbreak of respiratory syncytial</cell><cell>conversion (RS) can be prevented even in non-responders to hep-</cell></row><row><cell></cell><cell>virus in a bone marrow transplant center. J Infect Dis 165(6):987-</cell><cell>atitis B vaccine after allogeneic stem cell transplantation: long-</cell></row><row><cell></cell><cell>993</cell><cell>term analysis of intervention in RS with vaccine for patients with</cell></row><row><cell cols="2">14. Whimbey E et al (1995) Combination therapy with aerosolized</cell><cell>previous HBV infection. Transpl Infect Dis 16(5):797-801</cell></row><row><cell></cell><cell>ribavirin and intravenous immunoglobulin for respiratory syncy-</cell><cell>34. Peffault de Latour R et al (2008) Allogeneic hematopoietic cell</cell></row><row><cell></cell><cell>tial virus disease in adult bone marrow transplant recipients. Bone</cell><cell>transplant in HCV-infected patients. J Hepatol 48(6):1008-1017</cell></row><row><cell></cell><cell>Marrow Transplant 16(3):393-399</cell><cell>35. de Latour Peffault R (2004) Long-term outcome of hepatitis C</cell></row><row><cell cols="2">15. Taylor GS, Vipond IB, Caul EO (2001) Molecular epidemiology</cell><cell>infection after bone marrow transplantation. Blood 103(5):1618-</cell></row><row><cell></cell><cell>of outbreak of respiratory syncytial virus within bone marrow</cell><cell>1624</cell></row><row><cell></cell><cell>transplantation unit. J Clin Microbiol 39(2):801-803</cell><cell>36. Locasciulli A et al (1989) Predictability before transplant of he-</cell></row><row><cell cols="2">16. McWilliam Leitch EC et al (2001) Dietary effects on the microbi-</cell><cell>patic complications following allogeneic bone marrow transplan-</cell></row><row><cell></cell><cell>ological safety of food. Proc Nutr Soc 60(2):247-255</cell><cell>tation. Transplantation 48(1):68-72</cell></row><row><cell cols="2">17. Boyle NM et al (2014) Bacterial foodborne infections after hema-</cell><cell>37. Lee JH et al (2005) Decreased incidence of hepatic veno-occlusive</cell></row><row><cell></cell><cell>topoietic cell transplantation. Biol Blood Marrow Transplant</cell><cell>disease and fewer hemostatic derangements associated with intra-</cell></row><row><cell></cell><cell>20(11):1856-1861</cell><cell>venous busulfan vs oral busulfan in adults conditioned with bu-</cell></row><row><cell cols="2">18. Allegranzi B, Pittet D (2009) Role of hand hygiene in healthcare-</cell><cell>sulfan + cyclophosphamide for allogeneic bone marrow transplan-</cell></row><row><cell></cell><cell>associated infection prevention. J Hosp Infect 73(4):305-315</cell><cell>tation. Ann Hematol 84(5):321-330</cell></row><row><cell cols="2">19. CE1-7 (2000) Guidelines for preventing opportunistic infections</cell><cell>38. van der Eijk AA et al (2014) Hepatitis E virus infection in hema-</cell></row><row><cell></cell><cell>among hematopoietic stem cell transplant recipients. MMWR</cell><cell>topoietic stem cell transplant recipients. Curr Opin Infect Dis</cell></row><row><cell></cell><cell>Recomm Rep 49(RR-10)1-125</cell><cell>27(4):309-315</cell></row><row><cell cols="2">20. Daeschlein G et al (2007) Hygienic safety of reusable tap water</cell><cell>39. Versluis J et al (2013) Hepatitis E virus: an underestimated oppor-</cell></row><row><cell></cell><cell>filters (Germlyser) with an operating time of 4 or 8 weeks in a</cell><cell>tunistic pathogen in recipients of allogeneic hematopoietic stem</cell></row><row><cell></cell><cell>haematological oncology transplantation unit. BMC Infect Dis 7:45</cell><cell>cell transplantation. Blood 122(6):1079-1086</cell></row><row><cell cols="2">21. Zhou ZYet al (2014) Removal of waterborne pathogens from liver</cell><cell>40. le Coutre P et al (2009) Reactivation of hepatitis E infection in a</cell></row><row><cell></cell><cell>transplant unit water taps in prevention of healthcare-associated</cell><cell>patient with acute lymphoblastic leukaemia after allogeneic stem</cell></row><row><cell></cell><cell>infections: a proposal for a cost-effective, proactive infection con-</cell><cell>cell transplantation. Gut 58(5):699-702</cell></row><row><cell></cell><cell>trol strategy. Clin Microbiol Infect 20(4):310-314</cell><cell>41. Bettinger D et al. (2014) Chronic hepatitis E virus infection fol-</cell></row><row><cell cols="2">22. Cervia JS et al (2010) Point-of-use water filtration reduces</cell><cell>lowing allogeneic hematopoietic stem cell transplantation: an im-</cell></row><row><cell></cell><cell>healthcare-associated infections in bone marrow transplant recip-</cell><cell>portant differential diagnosis for graft versus host disease. Ann</cell></row><row><cell></cell><cell>ients. Transpl Infect Dis 12(3):238-241</cell><cell>Hematol 94(2):359-360</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Ann Hematol (2016) 95:1435-1455</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Allogeneic hematopoietic stem cell transplantation: complications and results</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Tabbara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1558" to="1566" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Management of infections complicating allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Hiemenz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Hematol</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="289" to="312" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies-guidelines of the Infectious Diseases Working Party</title>
		<author>
			<persName><forename type="first">H</forename><surname>Einsele</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hutter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Zaia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="284" to="295" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Long-term control of HIV by CCR5 Delta32/ Delta32 stem-cell transplantation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hutter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="692" to="698" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hutter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="2437" to="2438" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Henrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">207</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1694" to="1702" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">VDRL screening and haemopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Au</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Lie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Cheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1027" to="1028" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Martino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="67" to="78" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques</title>
		<author>
			<persName><forename type="first">H</forename><surname>Fricker-Hidalgo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="e9" to="e15" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="165" to="173" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research</title>
		<author>
			<persName><forename type="first">D</forename><surname>Menzies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Comstock</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="340" to="354" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Comparison of the QuantiFERON-TB gold in-tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Moon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="104" to="109" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in highrisk patients-review of the literature from a clinical perspective</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Biehl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Rev Microbiol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="16" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Liss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infection</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="613" to="619" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Zirakzadeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="385" to="392" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker?</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Dubberke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="813" to="819" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in nonepidemic situations</title>
		<author>
			<persName><forename type="first">M</forename><surname>Thouverez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Talon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bertrand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="838" to="841" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit</title>
		<author>
			<persName><forename type="first">S</forename><surname>Blot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="575" to="579" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures</title>
		<author>
			<persName><forename type="first">P</forename><surname>Frere</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="745" to="749" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">How to manage infections caused by antibiotic resistant gram-negative bacteria -EBMT Educational Meeting from the severe aplastic anaemia and infectious diseases working parties</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mikulska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Drug Targets</title>
		<imprint>
			<date type="published" when="2014">2015. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Bacterial infections in hematopoietic stem cell transplantation recipients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mikulska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Bono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Viscoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Hematol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="451" to="458" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Hammond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Baden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Hematol Malig Rep</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="97" to="103" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Bucaneve</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="977" to="987" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gafter-Gvili</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">D004386</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cullen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="988" to="998" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions</title>
		<author>
			<persName><forename type="first">L</forename><surname>Leibovici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1743" to="1751" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cruciani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="4127" to="4137" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kimura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="13" to="25" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ochs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Weisdorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">1-2</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ochs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="3979" to="3986" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kulkarni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3683" to="3686" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Analysis of sepsis in allogeneic bone marrow transplant recipients: a single-center study</title>
		<author>
			<persName><forename type="first">H</forename><surname>Mitsui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Chemother</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="238" to="242" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Taur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1174" to="1182" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Taur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="905" to="914" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Shono</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">339</biblScope>
			<biblScope unit="page" from="339" to="371" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study</title>
		<author>
			<persName><forename type="first">De</forename><surname>Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="879" to="883" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Pneumocystis carinii pneumonitis following bone marrow transplantation</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">Z</forename><surname>Tuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dennison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Weisdorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="267" to="272" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="573" to="580" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="issue">9148</biblScope>
			<biblScope unit="page" from="201" to="203" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="1627" to="1632" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Successful chemoprophylaxis for Pneumocystis carinii pneumonitis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">297</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="1419" to="1426" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Stein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1705" to="1709" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Stern</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">D005590</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation</title>
		<author>
			<persName><forename type="first">O</forename><surname>Lyytikainen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1057" to="1059" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Vasconcelles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="35" to="43" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients</title>
		<author>
			<persName><forename type="first">H</forename><surname>Green</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">D005590</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/ sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Colby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="897" to="902" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT</title>
		<author>
			<persName><forename type="first">H</forename><surname>Link</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="403" to="406" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Marras</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="66" to="74" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="369" to="376" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Souza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1467" to="1471" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">No occurrence of Pneumocystis jiroveci (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tomonari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="303" to="307" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS</title>
		<author>
			<persName><forename type="first">W</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="1521" to="1527" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>El-Sadr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="1889" to="1895" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Kontoyiannis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1091" to="1100" />
			<date type="published" when="2001">2010. 2001-2006</date>
		</imprint>
	</monogr>
	<note>: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients</title>
		<author>
			<persName><forename type="first">R</forename><surname>Martino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="475" to="482" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">The innate immune response to Aspergillus fumigatus</title>
		<author>
			<persName><forename type="first">V</forename><surname>Balloy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chignard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Microbes Infect</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="919" to="927" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experience</title>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="316" to="321" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Garcia-Vidal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1041" to="1050" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Post</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="189" to="195" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Lewis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mycoses</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="638" to="645" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sinko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="106" to="109" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period</title>
		<author>
			<persName><forename type="first">G</forename><surname>Chamilos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="986" to="989" />
			<date type="published" when="1989">2006. 1989-2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cordonnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="955" to="963" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cordonnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1762" to="1768" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Prophylaxis and treatment of invasive candidiasis in the intensive care setting</title>
		<author>
			<persName><forename type="first">L</forename><surname>Ostrosky-Zeichner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="739" to="744" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">I</forename><surname>Paphitou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ostrosky-Zeichner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Rex</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Mycol</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="235" to="243" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Wenzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gennings</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="S389" to="S393" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Forty-one recent cases of invasive zygomycosis from a global clinical registry</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ruping</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="296" to="302" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry</title>
		<author>
			<persName><forename type="first">D</forename><surname>Neofytos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="265" to="273" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Cornely</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="2078" to="2085" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Marty</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(16)00071-2</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Maertens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="760" to="769" />
			<date type="published" when="2016">2016. 10020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mousset</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncology</title>
		<imprint>
			<date type="published" when="2014">2014</date>
			<publisher>DGHO</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="13" to="32" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Wingard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="5111" to="5118" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">hematopoietic stem cell transplant recipients</title>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1096" to="1097" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Zaia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="737" to="743" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Boeckh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1800" to="1805" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Erard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">196</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="266" to="270" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Thomson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1065" to="1069" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kanda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="689" to="692" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gilbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bestman-Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Boivin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Resist Updat</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="88" to="114" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin</title>
		<author>
			<persName><forename type="first">N</forename><surname>Kroger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1060" to="1071" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Boeckh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Nichols</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2003" to="2008" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME)</title>
		<author>
			<persName><forename type="first">T</forename><surname>Thiele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transfusion</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2620" to="2626" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Narvios</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="499" to="501" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?</title>
		<author>
			<persName><forename type="first">N</forename><surname>Kekre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1719" to="1724" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bowden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="246" to="250" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">A comparison of filtered leukocytereduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bowden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="3598" to="3603" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="227" to="234" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte</title>
		<author>
			<persName><forename type="first">T</forename><surname>De Witte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="964" to="968" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Narvios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lichtiger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="749" to="752" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Zaia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="782" to="785" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nagler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">3-4</biblScope>
			<biblScope unit="page" from="127" to="132" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schmidt-Hieber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Hematol</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="877" to="885" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease</title>
		<author>
			<persName><forename type="first">H</forename><surname>Einsele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">338</biblScope>
			<biblScope unit="page" from="1170" to="1172" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1971" to="1979" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy</title>
		<author>
			<persName><forename type="first">S</forename><surname>O'brien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1816" to="1819" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Boeckh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="10" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. the Nordic BMT Group</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ruutu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="233" to="236" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Zikos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="132" to="137" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Meyers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">318</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="70" to="75" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Winston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="749" to="758" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ljungman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="3050" to="3056" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vusirikala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="265" to="270" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Boeckh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">172</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="939" to="943" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Winston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="5403" to="5410" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Avery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplant Infect Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="489" to="496" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Marty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="284" to="292" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Marty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="1227" to="1236" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Chemaly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="1781" to="1789" />
			<date type="published" when="2014">2014. 19</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Kharfan-Dabaja</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="290" to="299" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Curtis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="2208" to="2216" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Bertz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1563" to="1570" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Oertel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Riess</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Recent Results Cancer Res</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="89" to="95" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="53" to="59" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="550" to="555" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Meerbach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Virol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="441" to="454" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gruhn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1023" to="1025" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Rooney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1549" to="1555" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections</title>
		<author>
			<persName><forename type="first">U</forename><surname>Gerdemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Ther</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1622" to="1632" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Trop</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="236" to="244" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ruskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lariviere</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">337</biblScope>
			<biblScope unit="page" from="468" to="471" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Prospective study of toxoplasma reactivation by polymerase chain reaction in allogeneic stem-cell transplant recipients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bretagne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="127" to="132" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Quality control for the diagnosis of Toxoplasma gondii reactivation in SCT patients using PCR assays</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Costa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="527" to="528" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS</title>
		<author>
			<persName><forename type="first">C</forename><surname>Katlama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="268" to="275" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group</title>
		<author>
			<persName><forename type="first">D</forename><surname>Podzamczer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="175" to="180" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance</title>
		<author>
			<persName><forename type="first">C</forename><surname>Katlama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atovaquone Expand Access Group AIDS</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1107" to="1112" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Response to hepatitis A vaccination in immunocompromised travelers</title>
		<author>
			<persName><forename type="first">Garcia</forename><surname>Garrido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="378" to="385" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors</title>
		<author>
			<persName><forename type="first">W</forename><surname>Yeo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Virol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="299" to="307" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Moses</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Virol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1560" to="1563" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/ hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Locasciulli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="295" to="300" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor</title>
		<author>
			<persName><forename type="first">A</forename><surname>Knoll</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Viral Hepat</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="478" to="483" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?</title>
		<author>
			<persName><forename type="first">P</forename><surname>Mahale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Okhuysen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Torres</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">e1</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 * Amsterdam, The NetherlandsSpecial Reporting on:* Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection* Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients* Sofosbuvir Plus</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Ghany</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="2043" to="2047" />
			<date type="published" when="2013">2014. 2013</date>
		</imprint>
	</monogr>
	<note>Therapy of hepatitis C-back to the future. Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype</note>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir* Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I</title>
		<author>
			<persName><forename type="first">*</forename><surname>Populations</surname></persName>
		</author>
		<author>
			<persName><surname>Daclatasvir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Weill Medical College at Cornell</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1" to="18" />
		</imprint>
	</monogr>
	<note>Gastroenterol Hepatol (N Y). Suppl 3</note>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Respiratory tract viral infections in bone marrow transplant patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Raboni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="142" to="146" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Roghmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1085" to="1088" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Sullivan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematol Am Soc Hematol Educ Program</title>
		<imprint>
			<biblScope unit="page" from="392" to="421" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit</title>
		<author>
			<persName><forename type="first">N</forename><surname>Lehners</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1548" to="1553" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Influenza vaccination in patients with cancer: factors associated with vaccination practices for patients and their household members</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Ariza-Heredia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1239" to="1241" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Dykewicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="19S" to="22S" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Cortez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="834" to="838" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions</title>
		<author>
			<persName><forename type="first">P</forename><surname>Robinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transfus Med Rev</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S3" to="S8" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>Suppl 1</note>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Sullivan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">323</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="705" to="712" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Winston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="12" to="18" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Raanani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol : Off J Am Soc Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="770" to="781" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">P</forename><surname>Raanani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">D006501</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cordonnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="8" to="18" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schmidt-Hieber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="185" to="192" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Norlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="267" to="273" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">NIH conference. New insights into common variable immunodeficiency</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Sneller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="720" to="730" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Kerr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="114" to="118" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Granulocyte-colony-stimulating factormobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage</title>
		<author>
			<persName><forename type="first">A</forename><surname>Oza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transfusion</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="14" to="23" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b156">
	<monogr>
		<title level="m" type="main">Guideline on clinical evaluation of new vaccines</title>
		<author>
			<persName><forename type="middle">M A</forename><surname>Ema ; E</surname></persName>
		</author>
		<ptr target="EMEA/CHMP/VWP/164653/2005" />
		<imprint>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main">Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dignani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="263" to="267" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="770" to="779" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main">One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation</title>
		<author>
			<persName><forename type="first">V</forename><surname>Erard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="3071" to="3077" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group</title>
		<author>
			<persName><forename type="first">K</forename><surname>Oshima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="421" to="427" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main">Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Asano-Mori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="472" to="476" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main">Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Einsele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="2815" to="2820" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main">Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">P</forename><surname>Reusser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1159" to="1164" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main">Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Einsele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="3002" to="3008" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main">Valganciclovir is safe and effective as preemptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">E</forename><surname>Ayala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="851" to="856" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main">Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Burns</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="945" to="951" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main">A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Verdonck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="901" to="907" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main">Ex vivo expansion and prophylactic infusion of CMV-pp 65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Micklethwaite</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="707" to="714" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main">Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Lau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="702" to="709" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main">Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Loomba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="519" to="528" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main">A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1001" to="1010" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main">Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tamori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1715" to="1721" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b173">
	<analytic>
		<title level="a" type="main">A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience</title>
		<author>
			<persName><forename type="first">J</forename><surname>Shang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="581" to="586" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b174">
	<analytic>
		<title level="a" type="main">The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. a real life experience from a tertiary center</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Koskinas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Intern Med</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="768" to="771" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b175">
	<analytic>
		<title level="a" type="main">Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts</title>
		<author>
			<persName><forename type="first">J</forename><surname>Leong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatol Res</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1248" to="1252" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b176">
	<analytic>
		<title level="a" type="main">Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine</title>
		<author>
			<persName><forename type="first">T</forename><surname>Chiba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="220" to="223" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b177">
	<analytic>
		<title level="a" type="main">High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients</title>
		<author>
			<persName><forename type="first">K</forename><surname>Matsue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="357" to="364" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b178">
	<analytic>
		<title level="a" type="main">A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Foppa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="187" to="189" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b179">
	<analytic>
		<title level="a" type="main">Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS</title>
		<author>
			<persName><forename type="first">C</forename><surname>Katlama</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="189" to="191" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b180">
	<analytic>
		<title level="a" type="main">An open study of the pyrimethamineclindamycin combination in AIDS patients with brain toxoplasmosis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Leport</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="557" to="558" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b181">
	<analytic>
		<title level="a" type="main">Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cordonnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1392" to="1401" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b182">
	<analytic>
		<title level="a" type="main">Immune reconstitution after allog en ei c t ran sp l an ta ti on</title>
		<author>
			<persName><forename type="first">R</forename><surname>Seggewiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Einsele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="3861" to="3868" />
			<date type="published" when="2010">2010. 19</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b183">
	<analytic>
		<title level="a" type="main">Rituximab-treated patients have a poor response to influenza vaccination</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Eisenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="388" to="396" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b184">
	<analytic>
		<title level="a" type="main">Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin&apos;s lymphoma patients treated with rituximab-containing regimens</title>
		<author>
			<persName><forename type="first">D</forename><surname>Bedognetti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="6044" to="6055" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b185">
	<analytic>
		<title level="a" type="main">The response to vaccination against influenza A (H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab</title>
		<author>
			<persName><forename type="first">A</forename><surname>Berglund</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Oncol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1212" to="1220" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b186">
	<analytic>
		<title level="a" type="main">Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: A randomized open-label trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Juergens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Vaccin Immunother</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">5</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b187">
	<analytic>
		<title level="a" type="main">Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="26" to="34" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b188">
	<analytic>
		<title level="a" type="main">Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Burrows</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Immunol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1726" to="1736" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b189">
	<analytic>
		<title level="a" type="main">Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients</title>
		<author>
			<persName><forename type="first">N</forename><surname>Dhedin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="585" to="591" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b190">
	<analytic>
		<title level="a" type="main">Immunity after (re) vaccination of paediatric patients following haematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Olkinuora</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Paediatr</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="e373" to="e377" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b191">
	<analytic>
		<title level="a" type="main">Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD</title>
		<author>
			<persName><forename type="first">I</forename><surname>Hilgendorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="2825" to="2833" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b192">
	<analytic>
		<title level="a" type="main">Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1022" to="1030" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b193">
	<analytic>
		<title level="a" type="main">Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cordonnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="2730" to="2734" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b194">
	<analytic>
		<title level="a" type="main">Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Avetisyan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="257" to="263" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b195">
	<analytic>
		<title level="a" type="main">Influenza vaccination in hematopoietic SCT recipients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ljungman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Avetisyan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="637" to="641" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b196">
	<analytic>
		<title level="a" type="main">Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients</title>
		<author>
			<persName><forename type="first">D</forename><surname>Engelhard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b197">
	<analytic>
		<title level="a" type="main">Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gueller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1546" to="1550" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b198">
	<analytic>
		<title level="a" type="main">Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host</title>
		<author>
			<persName><forename type="first">H</forename><surname>De Lavallade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="307" to="314" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b199">
	<analytic>
		<title level="a" type="main">Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Inaba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="109" to="117" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b200">
	<analytic>
		<title level="a" type="main">Pertussis vaccine trials in the 1990s</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Lambert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S4" to="S9" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b201">
	<analytic>
		<title level="a" type="main">Immune responses to pertussis vaccines and disease</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Berbers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S10" to="S15" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b202">
	<analytic>
		<title level="a" type="main">A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT</title>
		<author>
			<persName><forename type="first">T</forename><surname>Parkkali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="933" to="938" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b203">
	<analytic>
		<title level="a" type="main">Response to tetanus toxoid immunization after allogeneic bone marrow transplantation</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ljungman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="496" to="500" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b204">
	<analytic>
		<title level="a" type="main">Immune status and immune response to diphtheria-tetanus and polio vaccines in allogeneic bone marrowtransplanted thalassemic patients</title>
		<author>
			<persName><forename type="first">Li</forename><surname>Volti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="225" to="227" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b205">
	<analytic>
		<title level="a" type="main">Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Dengler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">7-8</biblScope>
			<biblScope unit="page" from="867" to="874" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b206">
	<analytic>
		<title level="a" type="main">Response to immunization against polio after allogeneic marrow transplantation</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ljungman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Duraj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Magnius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="89" to="93" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b207">
	<analytic>
		<title level="a" type="main">Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Parkkali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">APMIS</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="383" to="388" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b208">
	<analytic>
		<title level="a" type="main">Immune response to polio vaccination in bone marrow transplant recipients</title>
		<author>
			<persName><forename type="first">D</forename><surname>Engelhard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="295" to="300" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b209">
	<analytic>
		<title level="a" type="main">Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT</title>
		<author>
			<persName><forename type="first">T</forename><surname>Parkkali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="663" to="668" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b210">
	<analytic>
		<title level="a" type="main">Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ljungman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1067" to="1069" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b211">
	<analytic>
		<title level="a" type="main">A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Parkkali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="179" to="188" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b212">
	<analytic>
		<title level="a" type="main">Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Barra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1021" to="1028" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b213">
	<analytic>
		<title level="a" type="main">Polysaccharide conjugate vaccine responses in bone marrow transplant patients</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Guinan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transplantation</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="677" to="684" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b214">
	<analytic>
		<title level="a" type="main">A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT</title>
		<author>
			<persName><forename type="first">T</forename><surname>Parkkali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="961" to="967" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b215">
	<analytic>
		<title level="a" type="main">Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation</title>
		<author>
			<persName><forename type="first">E</forename><surname>Vance</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="735" to="741" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b216">
	<analytic>
		<title level="a" type="main">Nontypeable Haemophilus influenzae invasive disease in The Netherlands: a retrospective surveillance study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Van Wessel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="e1" to="e7" />
			<date type="published" when="2001">2011. 2001-2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b217">
	<analytic>
		<title level="a" type="main">Invasive Haemophilus influenzae infections in Germany: impact of non-type b serotypes in the post-vaccine era</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kalies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">45</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b218">
	<analytic>
		<title level="a" type="main">Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Patel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="625" to="634" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b219">
	<analytic>
		<title level="a" type="main">Characteristics of Neisseria meningitidis isolates causing fatal disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jacobsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="734" to="744" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b220">
	<analytic>
		<title level="a" type="main">Meningococcal serotypes and serogroup B disease in north-west Europe</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Poolman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">8506</biblScope>
			<biblScope unit="page" from="555" to="558" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b221">
	<analytic>
		<title level="a" type="main">HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection</title>
		<author>
			<persName><forename type="first">M</forename><surname>Onozawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1226" to="1230" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b222">
	<analytic>
		<title level="a" type="main">Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants</title>
		<author>
			<persName><forename type="first">D</forename><surname>Jaffe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="2470" to="2475" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b223">
	<analytic>
		<title level="a" type="main">Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Idilman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transplant</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="438" to="443" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b224">
	<analytic>
		<title level="a" type="main">Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ljungman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="610" to="615" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b225">
	<analytic>
		<title level="a" type="main">Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants</title>
		<author>
			<persName><forename type="first">V</forename><surname>Spoulou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1187" to="1190" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b226">
	<analytic>
		<title level="a" type="main">Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>King</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="633" to="636" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b227">
	<analytic>
		<title level="a" type="main">Varicella vaccination in children after bone marrow transplantation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sauerbrei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="381" to="383" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b228">
	<analytic>
		<title level="a" type="main">Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Issa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="285" to="287" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b229">
	<analytic>
		<title level="a" type="main">Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Kussmaul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1602" to="1606" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b230">
	<analytic>
		<title level="a" type="main">Safety of live attenuated high-titer varicellazoster virus vaccine in pediatric allogeneic hematopoietic stem cell transplantation recipients</title>
		<author>
			<persName><forename type="first">T</forename><surname>Aoki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="771" to="775" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b231">
	<analytic>
		<title level="a" type="main">Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged &gt;/=2 years: an open-label study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cordonnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="313" to="323" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b232">
	<analytic>
		<title level="a" type="main">Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussisinactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Begue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Infect Dis J</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="804" to="809" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b233">
	<analytic>
		<title level="a" type="main">Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Meerveld-Eggink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1523" to="1530" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b234">
	<analytic>
		<title level="a" type="main">Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection</title>
		<author>
			<persName><forename type="first">K</forename><surname>Townsend</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">43</biblScope>
			<biblScope unit="page" from="5650" to="5656" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b235">
	<analytic>
		<title level="a" type="main">New considerations for Haemophilus influenzae type b vaccination</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Pinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Weart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Pharm</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="332" to="336" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b236">
	<monogr>
		<title level="m" type="main">Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease-Advisory Committee on Immunization Practices</title>
		<author>
			<persName><forename type="first">C</forename><surname>Centers For Disease</surname></persName>
		</author>
		<author>
			<persName><surname>Prevention</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
			<publisher>ACIP</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b237">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">MMWR Morb Mortal Wkly Rep</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">30</biblScope>
			<biblScope unit="page" from="1018" to="1019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b238">
	<analytic>
		<title level="a" type="main">Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults</title>
		<author>
			<persName><forename type="first">D</forename><surname>Toneatto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Vaccin</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="781" to="791" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b239">
	<analytic>
		<title level="a" type="main">Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Mahler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="145" to="149" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b240">
	<analytic>
		<title level="a" type="main">Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety</title>
		<author>
			<persName><forename type="first">J</forename><surname>Beran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Zent</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">34</biblScope>
			<biblScope unit="page" from="4275" to="4280" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b241">
	<analytic>
		<title level="a" type="main">Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Mcmahon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">200</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1390" to="1396" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b242">
	<analytic>
		<title level="a" type="main">A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="713" to="719" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b243">
	<analytic>
		<title level="a" type="main">Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J STD AIDS</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="595" to="600" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b244">
	<analytic>
		<title level="a" type="main">Immune status and the immune response to hepatitis B virus vaccine in thalassemic patients after allogeneic bone marrow transplantation</title>
		<author>
			<persName><forename type="first">Li</forename><surname>Volti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="157" to="160" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b245">
	<analytic>
		<title level="a" type="main">Two doses of MMR vaccine-sufficient to eradicate measles, mumps and rubella?</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fahlgren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Soc Med</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="129" to="135" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b246">
	<analytic>
		<title level="a" type="main">Immunization of adolescents: recommendations of the advisory committee on immunization practices, the american academy of pediatrics, the american academy of family physicians, and the american medical association</title>
	</analytic>
	<monogr>
		<title level="j">American Academy of Pediatrics Committee on Infectious Diseases</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="479" to="488" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>Pediatrics</note>
</biblStruct>

<biblStruct xml:id="b247">
	<analytic>
		<title level="a" type="main">Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine</title>
		<author>
			<persName><forename type="first">S</forename><surname>Nader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="13" to="17" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
